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Abstract 1
Abstract
The European Commission’s Joint Research 
centre (JRC) has undertaken a study to review 
available and emerging non-animal models in 
the field of respiratory tract diseases.
In a detailed analysis of the scientific literature, 
over 21,000 abstracts (11,636 non-cancer 
and 9,421 cancer) were scanned for relevant 
non-animal models of respiratory disease. 
From this, a total of 284 publications were 
finally identified as being promising candidate 
models according to a set of inclusion/
exclusion criteria. In vitro cell and tissue 
cultures, human ex vivo, in silico approaches 
were chiefly considered.
These models have been collated into a 
catalogue of biomedical disease models 
that will form a key knowledge source for 
researchers, educators and national ethics and 
funding authorities.
Simple cell culture models using immortalised 
cell lines are long-established, are inexpensive 
and quick, however they poorly reflect complex 
disease mechanism observed in vivo.
The emerging use of more physiologically-
relevant models of disease, such a 3D human 
tissue cultures, spheroids, organoids, and 
microfluidic ’lung-on-a-chip’ based systems 
shows immense promise for the development 
of in vitro model systems that can more 
accurately mimic human respiratory diseases.
This review shows that, while simple models 
are still prominent and have their uses, 
research focus has, in the past 5 years, being 
shifting towards increasingly sophisticated 
bioengineering approaches that recapitulate 
lung development, anatomy and physiologic 
functions in vitro. Such approaches hold the 
promise of more human-relevant disease 
models that can be used to elucidate 
mechanism of disease and aid in the 
development of new therapies.
Bioengineering approaches 
hold the promise of more 
human-relevant disease 
models that can be used 
to elucidate mechanism 
of disease and aid in the 
development of new therapies
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1  Introduction
Lung diseases such as asthma, chronic 
obstructive pulmonary disease (COPD), chronic 
respiratory infections, pulmonary fibrosis, 
and lung cancer are major contemporary 
health problems. Over 235 million people are 
affected by asthma and around 65 million 
live with moderate-to-severe COPD (Forum of 
Respiratory Societies, 2013).
Existing models of respiratory disease rely 
heavily on in vivo endpoints including (histo)
pathology, histology, mediator analysis and in 
diseases such as asthma, measures of airway 
(hyper)-responsiveness.
Despite increased prevalence of chronic airway 
diseases, the failure to translate promising 
drug candidates from animal models to 
humans has led to questions over the utility of 
in vivo studies in this area of disease research.
Failures in the current paradigm for drug 
development have resulted in soaring research 
and development costs and reduced numbers 
of new drug approvals. Over 90% of new drug 
programmes fail to progress to market and 
the rate of successful transition from phase 
II  to phase III clinical trial transition is far 
lower than other phases (Thomas et al., 2016) 
due largely to efficacy failures or unexplained 
toxicity.
This is particularly evident for drugs targeting 
respiratory disease, where the phase II to 
phase III transition rate, calculated at 29%, is 
lower than the overall average for all disease 
indications (Waring et al., 2015). Thus, there is 
now an increased interest in using alternative 
approaches, in particular non-animal models, 
as predictors of respiratory diseases.
There is a financial, as well as a scientific 
rationale, underpinning this. Respiratory 
diseases represent a huge burden worldwide, 
both economically and from a health 
perspective. In fact, chronic respiratory 
diseases are one of the leading causes of 
morbidity and mortality globally. There are 
many unmet needs regarding effective 
medications for respiratory diseases, and the 
inability of animal models to accurately 
recapitulate the full spectrum of clinical 
features of these conditions (e.g., asthma; 
COPD and cystic fibrosis) has a further negative 
impact on drug discovery.
The future development of safe and efficacious 
new therapies for respiratory diseases is 
therefore beginning to shift to models based 
on human data and the mechanistic basis 
for disease rather than the continued use 
of animal models which poorly reflect the 
clinical situation.
The purpose of this study is to develop a 
current overview of available and emerging 
non-animal models in the field of respiratory 
tract diseases, including information on 
their applications, biological relevance, and 
development status. This review aims to 
cover all existing and in-development non-
animal approaches to respiratory disease 
modelling, including in vitro, in silico and ex 
vivo approaches.
Chronic respiratory diseases 
are one of the leading causes 
of morbidity and mortality 
globally
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1.1 Overview of respiratory 
diseases
The US National Cancer Institute (NCI)1 defines 
respiratory disease as:
“A type of disease that affects the lungs 
and other parts of the respiratory system. 
Respiratory diseases include asthma, 
chronic obstructive pulmonary disease 
(COPD), pulmonary fibrosis, pneumonia, 
and lung cancer. Also called lung disorder 
and pulmonary disease.”
For this project, cystic fibrosis (CF), a genetic 
disorder that affects mostly the lungs, but also 
the pancreas, liver, kidneys, and intestine, is 
included in this definition.
1.1.1 Asthma
Asthma is a non-communicable inflammatory 
disease of the lung airways. It is characterised 
by variable and recurring symptoms, reversible 
airflow obstruction, and easily triggered 
bronchospasms manifested as recurrent 
attacks of breathlessness, wheezing, coughing 
and chest tightness, which vary in severity and 
frequency between individuals (World Health 
Organization, 2017a).
Asthma causes are not completely understood, 
but are thought to be due to a combination 
of genetic predisposition and environmental 
exposure to substances and particles that may 
irritate the airways or cause allergic reaction. 
Other potential triggers include medications 
such as aspirin (Kowalski et al., 2013) and 
beta blockers (Morales et al., 2017).
Diagnosis of asthma is typically based on the 
pattern of symptoms, response to therapy 
over time, and spirometry. Asthma is classified 
according to the frequency of symptoms, 
forced expiratory volume in one second (FEV1), 
1 https://www.cancer.gov/publications/dictionaries/cancer-terms/def/respiratory-disease
and peak expiratory flow rate (Khajotia, 2008). 
Asthma may be classified as atopic or non-
atopic, where atopy refers to a predisposition 
toward developing a type 1 hypersensitivity 
reaction (Horak et al., 2016).
There is currently no cure for asthma. Symptoms 
can be prevented or managed by avoiding 
triggers, such as allergens and irritants, and 
by the use of inhaled corticosteroids (ICS) 
in combination with inhaled long-acting B2 
agonist (LABA). Long-acting beta agonists 
(LABA) or antileukotriene agents may be used 
in addition to inhaled corticosteroids if asthma 
symptoms remain uncontrolled. Treatment of 
rapidly worsening symptoms is usually with 
an inhaled short-acting beta-2 agonist such 
as salbutamol and corticosteroids taken by 
mouth (Horak et al., 2016).
The World Health Organization (WHO) 
estimates that 235 million people currently 
suffer from asthma. According to the latest 
WHO estimates, released in December 2016, 
there were 383,000 deaths due to asthma in 
2015. Asthma presents a substantial burden 
to individuals and families and often restricts 
individuals’ activities over their lifetime. 
Although most asthma-related deaths occur in 
low- and lower-middle income countries, likely 
due to being under-diagnosed and under-
treated, the disease occurs in all countries 
regardless of their level of development 
(World Health Organization, 2017a).
Animal models of asthma aim to mimic the 
pathophysiology of human disease (Aun et 
al., 2017). Several animal species of animals 
have been used in experimental models of 
asthma, including Drosophila, rats, guinea 
pigs, cats, dogs, pigs, and primates. However, 
the most common species/strain studied is 
BALB/c mice, as they develop a good Th2-
biased immunological response (Nials and 
Uddin, 2008). Animal models typically include 
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two phases: sensitisation and challenge. 
Sensitisation is traditionally performed by 
intraperitoneal and subcutaneous routes, while 
intranasal instillation of allergens has been 
used to mimic human exposure to allergens 
by inhalation.
Few new drugs have made it to the market 
in the last 50 years. Most approaches cannot 
be translated to human disease, as asthma 
is a uniquely human condition. For example, 
mice do not develop asthma spontaneously, 
and so in order to create an animal model 
with symptoms of the disease, a protein such 
as ovalbumin is instilled into the airways to 
artificially induce the condition.
There are wide variations between animal 
species, protocols and allergens used. Recent 
approaches have tended to replace ovalbumin 
with the same aeroallergens that trigger 
clinical disease, for example house dust mites 
(Aun et al., 2017).
Development of innovative approaches in the 
study of human asthma has been slow. Human 
tissue and tissue engineering approaches 
show promise but are limited by access to 
normal human tissue and also to diseased 
tissue (Edwards et al., 2015).
The use of non-mammalian models 
(Caenorhabditis elegans, Drosophila, 
Dictyostelium discoideum and zebrafish) in 
respiratory disease research is almost non-
existent. They have, however, been used to 
understand the molecular mechanisms of 
diseases in other organ systems, suggesting 
that they may be useful alternatives for 
asthma research.
Mathematical models can provide new insights 
to improve understanding of asthma, and a 
number of these are under development. In 
silico approaches have been used, mainly in 
deposition modelling of inhaled therapies 
(Munro et al., 2018).
1.1.2 Chronic obstructive 
pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) 
is an umbrella term used to describe progressive 
lung diseases including emphysema and 
chronic bronchitis. The common terms 'chronic 
bronchitis' and 'emphysema' are no longer 
used, but are now included within the COPD 
diagnosis (World Health Organization, 2017b).
COPD is a chronic inflammatory lung disease 
that develops slowly and usually becomes 
apparent after 40 or 50 years of age. The 
most common symptoms of COPD are 
breathlessness (or a "need for air"), chronic 
cough, and sputum (mucus) production (World 
Health Organization, 2017b).
Chronic bronchitis is inflammation of the 
lining of the bronchial tubes, which carry 
air to and from the alveoli of the lungs. It is 
characterised by chronic cough and mucus 
(sputum) production.
Emphysema is a condition in which the alveoli 
at the end of the smallest air passages 
(bronchioles) of the lungs are destroyed as 
a result of damaging exposure to cigarette 
smoke and other irritating gases and 
particulate matter.
The leading cause of COPD is tobacco smoking. 
Long-term exposure to chemical irritants can 
also lead to COPD. Diagnosis usually involves 
imaging tests, blood tests, and lung function 
tests. There is no cure for COPD, but treatment 
can help ease symptoms, lower the chance of 
complications, and generally improve quality 
of life. Medications, supplemental oxygen 
therapy, and surgery are some forms of 
treatment (Balkissoon et al., 2011).
WHO has estimated a prevalence of 251 
million cases of COPD globally in 2016, with an 
estimated that 3.17 million deaths caused by 
the disease in 2015 (5% of all deaths globally 
in that year). More than 90% of COPD deaths 
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occur in low and middle income countries 
(World Health Organization, 2017b).
Animal models of COPD typically use mice, 
guinea pigs and rats. COPD is induced by 
exposure to cigarette smoke (CS), intra-tracheal 
lipopolysaccharide (LPS) and intranasal 
elastase. Parameters measured are mainly 
lung pathological data and lung inflammation 
(both inflammatory cells and inflammatory 
mediators) in most of the studies and tracheal 
responsiveness (TR) in only few studies. 
However, to date there is no standardised 
method or protocol for animal exposure to 
CS, and there is a wide diversity of methods 
by which a study on COPD in animals can 
be done. For example, the type of cigarettes 
used to generate smoke (commercial vs. 
research cigarettes, with or without a filter), 
the constituents of the CS used for exposures, 
delivery systems (whole body vs. nose-only), 
duration of exposure and most significantly, 
the dose of smoke delivered to the animals 
are important determinant factors that have 
yet to be standardised (Ghorani et al., 2017).
Although CS has been shown to induce 
many features of COPD in animals, including 
pulmonary infiltration of macrophages and 
neutrophils, airway fibrosis and emphysema, 
these still do not accuratley describe the 
human situation.
For example, mice do not produce mucus in 
their bronchial tract and therefore cannot 
represent this aspect of COPD. Animal models 
do not reflect that variable pathology and 
different stages of COPD severity in humans, 
and thus are restricted to modellling a limited 
number of characteristic features of COPD in 
the clinic. Also, several studies have shown 
that different strains of mice show various 
levels of sensitivity to CS challenge (Mortaz 
and Adcock, 2012).
Non-animal approaches to modelling COPD are 
developing but are still limited. For example, 
cell lines are not considered as physiologically 
complex enough, whereas reproducibility of 
primary cells is variable between donors. 3D 
epithelial cultures are more physiologically 
relevant, but also suffer from reproducibility 
issues across different donors. Ex vivo lung 
tissues, for example precision cut lung slices 
(PCLS) are the most physiologically relevant 
of non-whole organ ex vivo models and allow 
study of cell types/functions (macrophages, 
airway contractility, etc.) that are not available 
in other models. However availability of high 
quality tissue is low, and variabilty across 
donors is still an issue (Adamson et al., 2011; 
Benam et al., 2015).
1.1.3 Pulmonary fibrosis
Pulmonary fibrosis is a respiratory disease in 
which scars are formed in the lung tissues, 
resulting in stiffness and difficulty in breathing, 
which can eventually lead to respiratory 
failure, heart failure, or other complications. 
Scar formation through the accumulation of 
excess fibrous connective tissue in the lung 
parenchyma (fibrosis) leads to thickening of 
the walls, and causes reduced oxygen supply 
in the blood. This manifests as a perpetual 
shortness of breath (Sgalla et al., 2018).
Pulmonary fibrosis may be a secondary effect 
of other diseases, in particular interstitial lung 
diseases caused by autoimmune disorders, 
viral infections and bacterial infection (e.g., 
tuberculosis). Idiopathic pulmonary fibrosis 
(IPF) refers to a manifestation without any 
known cause. Current paradigms suggest 
that alveolar epithelial cell damage is a key 
initiating factor in IPF (Barratt et al., 2018).
Spontaneous pulmonary fibrosis is known to 
occur in other animal species, including dogs, 
horses, donkeys, and cats. To date, preclinical 
investigations of fibrosis have typically used 
mouse models of bleomycin (BLM)-induced 
pulmonary fibrosis. However there are several 
limitations that prevent direct translation to 
human IPF. Preclinical efficacy of currently 
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approved anti-fibrotic agents (pirfenidone and 
nintedanib) was tested only in the BLM-induced 
model, with results based on histologic end 
points such as collagen deposition that are not 
clinically relevant. Also, reproducibility issues 
are evident due to widely variable experimental 
procedures between labs, leading to a lack of 
consistent results. Animal size needs to be 
balanced with the statistical power needed 
to generate robust data and that insufficient 
reporting of experimental animal data or 
unpublished negative therapeutic results 
severely hamper the validity of experimental 
studies (Tashiro et al., 2017).
Current research is directed at identifying key 
biomarkers that may direct more clinically-
relevant results (Barratt et al., 2018).
Humanised in vitro models can enable the 
modelling fibrotic disease using human cells, 
and these are in theory more suitable than 
animal models in modelling human lung 
physiology, biology and immunity. Current in 
vitro models are limited as they only allow 
acute studies (1–2 days) and are primarily 
focused on TGF-β1 induced collagen production 
(Sundarakrishnan et al., 2018).
Precision cut lung slices (PCLS) recapitulate 
aspects of the human lung better than other 3D 
tissue models. The American Thoracic Society 
(ATS) has recommended using these systems 
to corroborate results obtained from bleomycin 
animal studies (Jenkins et al., 2017). Future 
work will involve comparative studies of anti-
fibrotic drug effects in PCLTs versus bleomycin 
administered animal models, so as to understand 
species differences in drug responses.
Past studies have created lung-on-chip devices 
for studying pulmonary fibrosis (fibrosis-
on-chip), but antifibrotic drug testing and 
mechanistic studies of fibrotic lung disease have 
not yet been fully developed. Lung spheroids 
and organoids are limited because they do not 
permit airway maturation. However, they also 
may be used to identify differences in drug 
responses between animal studies and organoid 
cultures (Sundarakrishnan et al., 2018).
1.1.4 Cystic fibrosis
Cystic fibrosis (CF) is an autosomal recessive 
genetic disorder that primarily affects the 
lungs, but also the pancreas, liver, kidneys, 
and intestine. In the lung, CF results in a 
progressive bronchiectasis, leading to difficulty 
breathing and coughing up mucus as a result 
of frequent lung infections, and ultimately to 
respiratory failure, which is the leading cause 
of death in patients with CF (Goetz and Ren, 
2019).
The cystic fibrosis transmembrane conductance 
regulator (CTFR) protein functions as a channel 
across the membrane of cells that produce 
mucus, sweat, saliva, tears, and digestive 
enzymes. The channel transports negatively 
charged chloride ions into and out of cells, 
regulating the movement of water in tissues, 
which is necessary for the production of 
thin, freely flowing mucus. Disease-causing 
mutations in the CFTR gene alter the production, 
structure, or stability of the chloride channel, 
resulting in the production of abnormally thick 
mucous which can subsequently blocks airways 
and glands, leading to the clinical symptoms.
The condition is diagnosed by a sweat test and 
genetic testing. There is no known cure. The 
average life expectancy is between 42 and 50 
years in the developed world. Lung problems 
are responsible for death in 80% of people 
with cystic fibrosis (Ong and Ramsey, 2015).
Most current knowledge of CF pathophysiology 
has been derived from animal models, in 
particular gene-targeted mouse models. 
However, mice models, in contrast to pigs and 
ferrets, do not spontaneously develop lung 
disease as seen in humans. Pigs and ferrets 
exhibit similar lung function and architecture 
with humans and at birth, however they lack 
inflammation (Semaniakou et al., 2019).
 Introduction 9
The main disadvantage of animal models of 
CF is the difficulty of keeping them alive long 
enough for study, as the animals typically die 
from intestinal obstruction soon after birth. 
Therefore, while animal studies may show 
lung pathology similar to that in CF patients, 
they are only based on experiments that have 
been conducted in a small number of animals, 
which are mostly newborn (Semaniakou et al., 
2019).
Conventional 2D cell culture models have been 
shown to be useful for preclinical research and 
testing, but they lack the structural complexity 
of intact organs (Cutting, 2015). The use of 
3D airway and intestinal organoid models in 
CF research is increasing; however the most 
developed models currently are intestinal 
organoids that exhibit key physiological 
differences between the gut and the airway 
mucosal surface, including the observation 
that there is no mucociliary clearance in the 
gastrointestinal tract (Awatade et al., 2018).
1.1.5 Lung cancer
Lung cancer, or lung carcinoma, is a malignant 
lung tumour characterised by uncontrolled 
cell growth in tissues of the lung, and which 
can metastasise to other organs and tissues. 
Most cancers that start in the lung (primary 
lung cancers) are carcinomas. Two main types 
are identified based on histology: small cell 
lung carcinoma (SCLC) and non-small cell 
lung carcinoma (NSCLC). The most common 
symptoms are coughing (including coughing 
up blood), weight loss, shortness of breath, 
and chest pains.
The majority (>85%) of cases of lung cancer 
are due to long-term tobacco smoking. Of the 
approximately 10–15% of cases that occur in 
people who have never smoked, a combination 
of genetic factors and exposure to radon 
gas, asbestos, second-hand smoke, or other 
2 https://www.wcrf.org/dietandcancer/cancer-trends/lung-cancer-statistics
forms of air pollution, or chronic infection, are 
implicated (Lemjabbar-Alaoui et al., 2015).
Worldwide in 2012, lung cancer occurred in 
1.8 million people and resulted in 1.6 million 
deaths, making it the most common cause of 
cancer-related death in men and second most 
common in women after breast cancer2.
Modelling lung cancer in non-animal models 
presents many challenges. Whereas analyses 
such as tumour DNA sequencing can be 
performed in cell cultures in vitro, the outcome 
of mutations are best assessed in the context 
of an intact organism. Mouse models of 
cancer are widely used as they can reproduce 
many features of human tumours, and allow 
for re-engineering of combinations of complex 
lesions found in human tumours, providing a 
basis to model distinct tumour characteristics 
such as metastatic behaviour and response to 
therapy (Kwon and Berns, 2013).
The OncoCilAir™ human 3D in vitro lung 
cancer model has been available since 2015, 
offering the advantage of reproducibility that 
is implied with a commercial model, and which 
is of utmost importance to deal with emerging 
Worldwide lung cancer 
represents the most common 
cause of cancer-related 
death in men and second 
most common in women 
after breast cancer
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issues with in vitro research beyond those 
that can be addressed with good cell culture 
practice (Pamies, 2018).
The use of patient-derived xenografts, where 
human tumour tissue is implanted into an 
animal in order to test different chemotherapy, 
has been discredited recently, as alterations in 
the tumours as they progress in vivo remove 
any resemblance to the patient’s disease (Ben-
David et al., 2017).
1.1.6 Respiratory infections
Respiratory infections such as pneumonia and 
tuberculosis present a challenging field of 
study due to an intricate relationship between 
the pathogenicity of microbes and the host's 
defences.
Pneumonia is usually caused by infection 
with viruses or bacteria and less commonly 
by other microorganisms, certain medications 
and conditions such as autoimmune diseases. 
Risk factors include other lung diseases such 
as cystic fibrosis, COPD, and asthma, diabetes, 
heart failure, a history of smoking, a poor 
ability to cough such as following a stroke, or 
a weak immune system.
Tuberculosis (TB) is caused by the bacillus 
Mycobacterium tuberculosis and is the leading 
cause of infection-related death globally. TB 
affects over 10.4 million new individuals per 
year and is estimated to exist in a latent form 
in around 2 billion people worldwide (World 
Health Organization, 2018).
Human models of virus-induced asthma and 
COPD exacerbations have been developed but 
their use is limited to study viral infections, 
for safety and ethical reasons. Animal models 
of respiratory infection are more widely used. 
Species utilised include primates, bovids, 
sheep, rabbits, guinea pigs and mice (Saturni 
et al., 2015).
Cattle have been widely used for modelling 
tuberculosis infections for vaccine development, 
as they are the natural host of Mycobacterium 
tuberculosis bovis, and they develop a disease 
very similar to humans (Rodriguez et al., 
2011). However, mice are the most common 
species used, principally for reasons of cost, 
ease of handling and opportunities for genetic 
manipulation (Bem et al., 2011).
Studies on mouse models are not limited to 
common viral and bacterial infections, but 
also to complex infections like pneumonia. 
Animals can be manipulated in different ways 
to investigate various aspects of diseases. 
For example, immunological insights into 
pneumonia have been gained by photon-
irradiation of mice subsequently challenged 
intra-tracheally with Klebsiella pneumonia 
(Keller et al., 2003).
In vitro models are often the first step to study 
a respiratory infection mechanism, allowing 
evaluation the role of single elements in order 
to clarify the pathways leading to respiratory 
infections. The interrelationship between 
individual elements can then be studied in a 
complex setting as an animal/human model. A 
more complex setting is represented by the ex 
vivo models, which consist of human samples 
that are infected in vitro.
In vitro models that recapitulate in vivo drug 
clearance profiles are increasingly important 
In vitro models are often 
the first step to study 
a respiratory infection 
mechanism in order to clarify 
the pathways involved
in pharmacodynamic studies. And although in 
vitro pharmacodynamic models cannot model 
all variables seen in vivo, they can provide 
valuable information for the drug development 
process and the determination of optimal 
dosing regimens (White, 2001).
1.2 Non-animal models of 
respiratory disease
Many scientific discoveries and therapies have 
shown promise in the animal model of choice 
but subsequently failed to replicate the results 
when translated to human beings. This is due to 
the huge differences in associated risk factors, 
course of disease, pathogenesis, chronicity, 
related pathologies and comorbidities, 
symptoms, and genetic influences between 
the species (Akhtar, 2015).
Airways epithelial cells are differentiated and 
polarised in vivo, this aids normal function of the 
tissue and is vital to recreate effective models of 
diseases such as cystic fibrosis, where location 
and activity of an ion channel are of exquisite 
importance to pathophysiology. Culturing cells 
at the air liquid interface (ALI) has the added 
advantage of promoting polarisation and the 
role of this in disease pathology, and also in 
modelling infections, has been recognised 
3 https://www.lungcancereurope.eu/lung-cancer/
In vitro models that 
recapitulate in vivo drug 
clearance profiles are 
increasingly important in 
pharmacodynamic studies
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(Hasan et al., 2018). Whilst models of infection 
were not a major focus on this project, we were 
interested in models of important respiratory 
conditions, specifically, pneumonia and TB. 
One of the major drawbacks of using animals 
to model infections is that the host-pathogen 
interactions are not recapitulated and 
differences in the immune response between 
animals and humans could create significant 
differences in disease progression and the 
ultimate resolution of infection. However, 
it is apparent that non-animal models are 
beginning to address thus and are becoming 
more complex, incorporating various different 
immune cells in order to increase complexity 
and physiological relevance (Iakobachvili and 
Peters, 2017).
This increase in complexity has led to more 
multidisciplinary approaches to create models, 
with a rise in the use of bioengineering 
approaches, to scale-up basic research models 
in order to create solutions for clinical problems 
such as lung transplantation. A growing 
number of tissue engineering approaches 
are exploring the potential to generate lung 
tissue ex vivo for transplantation (De Santis et 
al., 2018). We did not extensively explore the 
issue of generating tissue for clinical purposes 
through this project, but note that regenerative 
medicine is potentially a very important 
endpoint for in vitro modelling, and particularly 
for lung disease, given the high incidence and 
severity of these conditions globally.
Cancer remains a leading cause of morbidity and 
mortality globally and lung cancer specifically 
accounts for more deaths than breast and 
prostate cancer combined3. The rise in tissue 
engineering has enabled the development 
of complex three dimensional, ‘spheroid’ 
tumour models that take account of the niche 
surrounding the tumour and can facilitate 
studies of cell signalling within and outside of 
the tumour mass (Rodrigues et al., 2018).
In vitro models that 
recapitulate in vivo drug 
clearance profiles are 
increasingly important in 
pharmacodynamic studies
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1.2.1 In vitro 2D and 3D cultures
Cell cultures from primary and immortalised 
cell lines have traditionally been performed 
in two dimensions (2D), where the cells of a 
single type are grown submerged in nutrient 
medium on plastic or glass culture dishes. 
This has allowed for a consistent approach 
to the study of individual cell type features 
such as morphology, genetics, and physiologic 
response and enable high throughput 
applications, particularly in drug development.
However, despite these advantages, 2D cell 
culture has major drawbacks when compared 
with animal models of disease. Most obvious 
is that 2D systems cannot replicate the in 
vivo situation where tissues and organs 
are comprised of multiple cell types which 
function together as units through cellular 
communication and contact, as seen in the 
complexity of whole organs (Huh et al., 2011). 
2D cultures cannot reproduce the key features 
of the airways such as the formation of a 
differentiated, polarised epithelial barrier with 
different epithelial cell types. For example, cells 
in these system fail to undergo mucociliary 
differentiation (Marshall et al., 2015).
4 http://www.epithelix.com/products/mucilair
The development of three-dimensional (3D) 
air-liquid interface (ALI) cultures has enabled 
the creation of more physiologically accurate 
models recapitulate the pseudostratified 
mucociliary phenotype observed in vivo.
The defining feature of ALI culture is that the 
basal surface of the cells is in contact with liquid 
culture medium, whereas the apical surface 
is exposed to air. Airways epithelial cells, for 
example human bronchial epithelial cells 
(HBECs), are plated onto specialised culture 
inserts such as Transwells® or Snapwells™, 
and grow on a porous filter that physically 
separates the lung epithelial tissue from the 
underlying media. Cells can thus be induced 
to differentiate to create a pseudostratified 
epithelial layer. Ciliated and mucous-producing 
cells become polarised and take on features of 
in vivo tissue, including functional apical cilia 
and/or mucous secretion from goblet cells 
(Bals et al., 2004).
Air-liquid Interface (ALI) cultures of primary 
human epithelial tissue have been especially 
useful in understanding cellular mechanisms 
of cystic fibrosis (CF), allowing for the study 
of the cellular effects of CFTR mutations or 
defects in epithelial barrier function (Randell et 
al., 2011). ALI cultures are also used to study 
the effects of toxins such as cigarette smoke, 
environmental particles, or infectious agents 
on bronchial epithelial cells (Schamberger et 
al., 2015; Miller and Spence, 2017).
A number of commercial ALI systems have 
become available in recent years, for example 
the MucilAir™ human airway epithelia model4. 
These provide a well-characterised 3D model 
of several pathologies, thus allowing high data 
reproducibility.
3D cell culture also allows for the co-culture 
of different cell types along with a synthetic 
scaffolding and an extracellular matrix (ECM), 
such as hydrogels, which leads to self-
Three-dimensional (3D) 
air-liquid interface (ALI) 
cultures can recapitulate 
the pseudostratified 
mucociliary phenotype 
observed in vivo
The rise in tissue 
engineering has enabled 
the development 
of complex three-
dimensional, ‘spheroid’ 
tumour models
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assembly of the tissue into various forms that 
partially reflect the structure of the lung.
Spheroids are simple 3D models generated 
by spontaneous cell aggregation, and do not 
require any external scaffold, instead relying 
on cellular contact and spontaneous ECM 
deposition to bind them together. Cell-only 
spheroid size is limited due to the absence 
of vasculature, which also makes long-term 
culture (beyond days) difficult (Barrila et al., 
2010).
Spheroids of different co-cultured cell types 
can develop physiologic cell-cell contacts 
and secrete mucins similar to in vivo tissues, 
allowing them to be used to study cell 
metabolism, necrosis, angiogenesis, and 
adhesion (Konar et al., 2016). They are widely 
used for drug screening and also provide a 
platform for various electrophysiological and 
immunohistochemical studies (Mueller-Klieser, 
1997).
Spheroids also develop similar characteristics 
to in vivo tumors and are widely used in 
cancer biology to study invasion, metastasis, 
antineoplastic drugs, radioresponsiveness, and 
hypoxic effects (Weiswald et al., 2015).
Recent work has seen the development of 
in vitro models of the human lung using 
embryonic and induced pluripotent stem 
cells (hPSCs). This provides a unique tool for 
disease modelling and drug discovery, and 
show promise for the study of regenerative 
medicine (Dye et al., 2016).
1.2.2 Ex vivo tissue culture
Ex vivo tissue explant cultures involve the 
growth of human organ explants on various 
substrates, which has the advantage of 
retaining that microarchitecture, functions and 
molecular interplay of the lung and airways.
A common method is the production of 
precision cut lung slices (PCLS), which offer 
a phenotypically-accurate model of lung 
behaviour. PCLS of defined thickness are 
sectioned from lung tissues using a vibratome, 
before being placed in fresh media. The slices 
can then be stimulated with drugs or pathogens 
for study of specific characteristics of normal 
and diseased lungs. PCLS-based lung models 
have been used to study the effects of allergens, 
stimulated bronchodilators, smooth muscle 
contractility, smoking-related toxicology, and 
the effects of infectious diseases (Sanderson, 
2011).
Although explant cultures make it possible to 
study in vivo microenvironments in vitro, they 
are difficult to obtain and optimise. The majority 
of tissue explants are obtained from thoracic 
surgery, mostly involving lung carcinoma, but 
whole lungs rejected for transplantation are 
also used. Road traffic accidents are the major 
source of tissue available from asthmatics 
and these are rarely available. The variability 
of source organs can create experimental 
variance, and the handling of organs introduces 
possibilities for contamination (Sanderson, 
2011; Zscheppang et al., 2018).
Three-dimensional (3D) 
air-liquid interface (ALI) 
cultures can recapitulate 
the pseudostratified 
mucociliary phenotype 
observed in vivo
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1.2.3 Organoids
Recent advances in tissue engineering have 
resulted in the generation of multicellular 
tissue models, called organoids that can reflect 
the functional properties of human tissue 
and organs. An organoid is a minituarised 3D 
representation of an organ that accurately 
replicates the histological and functional 
aspects of in vivo tissue (Dye et al., 2015).
Lung organoid culture involves the 
culture of epithelial stem and progenitor 
cells extracellular matrix (ECM) which is 
supplemented with growth factors and/or 
stromal cells. These organoids then self-
organise into complex structures that retain 
clusters of epithelial cells from multiple 
lineages. The most common 3D environment 
used for the formation of organoids are 
hydrogels, (e.g., Matrigel), that contain mixtures 
of extracellular matrix components, including 
laminin and collagen (Nadkarni et al., 2016).
Depending on the origin of the starting cells, 
organoids can grow into spheres called, for 
example, bronchospheres, bronchioalveolar 
spheres or alveolospheres. Lung organoids 
recapitulate features of the lung including 
heterogeneous cell composition, spatial 
organisation, and retention of a stem cell 
population, giving them the capacity to self-
renew and differentiate.
Lung organoids were initially developed using 
combinations of induced pluripotent stem 
cells in 3D culture conditions. Subsequently, 
resident progenitor cells from adult tissues 
were cultured in supportive 3D systems, and 
these can also be induced to form organoids 
(Dye et al., 2016).
Lung organoids represent a physiologically 
relevant culture system, particularly of the 
distal (alveolar) lung. Thus they make for highly 
promising models in basic and translational 
approaches such as disease modelling and 
drug screening.
1.2.4 Lung-on-a-chip
Huh and colleagues (Huh et al., 2010) first 
designed a multifunctional, microfluidic device 
to emulate the human alveolar-capillary 
interface, seeking to reproduce key structural, 
functional, and mechanical properties of 
the alveolar-capillary interface in an effort 
to create a highly relevant model of lung 
microphysiology.
For the formation of an alveolar-capillary 
interface, human alveolar epithelial cells and 
pulmonary microvascular endothelial cells are 
seeded in the device chambers and allowed to 
adhere to matrix-coated membrane surfaces. 
The microchannels are then perfused with 
culture media to support cell growth. The 
alveolar epithelial cells are exposed to air, 
which induces differentiation while being fed 
from the basal side, leading to the formation 
of a microengineered barrier tissue composed 
of the alveolar epithelium and capillary 
endothelium in close proximity.
The lung-on-a-chip model provides new 
opportunities to reconstitute organ-level 
physiological functions that arise from complex 
interplay between multiple tissue types in the 
living human lung.
The lung-on-a-
chip provides new 
opportunities to 
reconstitute organ-level 
physiological functions 
Lung organoids represent 
relevant models in 
basic and translational 
approaches such as 
disease modelling and 
drug screening
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For example, introduction of pro-inflammatory 
cytokines and bacteria into the upper alveolar 
compartment induced activation of the 
endothelial cells on the opposite side of the 
membrane and their increased expression of 
adhesion molecules.
The device can also be used in toxicology 
studies, for example to examine intracellular 
reactive oxygen species (ROS) in response to 
alveolar exposure to nanoparticles. Further, 
it has been shown to effectively model 
pulmonary edema in human lungs (Huh et al., 
2012a).
Further development has led to a “breathing 
lung-on-a-chip” microdevice which recreates 
physiological breathing movements by 
applying a vacuum to the side chambers 
and causing mechanical stretching of the 
poly(dimethylsiloxane) membrane forming the 
alveolar-capillary barrier (Huh, 2015).
The development of effective models for 
respiratory research is vital for better 
understanding of human disease processes 
and mechanisms, for revealing possible 
sensitivities and toxicities and for finding and 
addressing novel drug targets. Our literature 
search revealed many salient reviews on 
this topic, that whilst we could not use them 
for extracting methodological data about 
individual models, were still very important for 
revealing the state-of-the-art. For example, 
in terms of investigation of lung toxicity, it 
is widely recognised that the ‘traditional’ 
submerged cultures are unsuitable for 
modelling the impact of an inhaled chemical 
onto airways epithelium and so models 
need to employ the air-liquid interface (ALI) 
platform (Hiemstra et al., 2018; Upadhyay 
and Palmberg, 2018). Thus, the models that 
we have selected for future analysis in our 
collection focus on this set-up.
In summary, the enhanced availability of human 
cell types, both primary and immortalised cell 
lines has enabled more labs to use human 
cells in their research.
1.2.5 In silico and mathemathical 
approaches
Computational modelling of the lung has 
traditionally focused on representing lung 
functions, both normally in the healthy state 
and in the case of diseases, and have mainly 
focused on the modelling of the deposition of 
inhaled therapeutics.
The small airways and gas exchange tissue 
of the lung are relatively inaccessible to 
measurement and precise dosing with inhaled 
therapeutics. This has limited the development 
of new therapies for common lung diseases.
In response to this need, computational 
models can aid in the development of an 
overall framework so that its behaviour can 
be predicted in ways that are beyond direct 
measurement techniques (Tawhai and Bates, 
2015).
Various modelling approaches have been 
developed that range from continuum models 
of tissue, airway, or fluid mechanics, to agent-
based models of pathogen-host interactions.
For example, bronchoconstriction involves 
complex interactions among the small airways 
The lung-on-a-
chip provides new 
opportunities to 
reconstitute organ-level 
physiological functions 
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that result in regions of poor ventilation 
(ventilation defects, VDefs) in the lungs. 
Mathematical modeling of the mechanisms 
involved in bronchoconstriction is now 
possible, allowing for insights into the complex 
airway behaviour that leads to VDefs (Winkler 
et al., 2015). Computational models are 
available to assess patient response to acute 
disease (Burrowes et al., 2011), and these 
are being expanded towards the development 
of computational models of patient-specific 
chronic disease (Clark et al., 2015).
In the area of pulmonary disease research, 
computational (in silico) methods have 
become more prominent in the investigation 
of drug deposition and absorption, including 
the development of physiologically-based 
pharmacokinetic (PBPK) modelling and 
quantitative structure activity relationships 
(QSAR) to aid in the screening of promising 
drug candidates.
Inhalation is the administration route of 
choice for the delivery of drugs to treat 
respiratory diseases such as asthma and 
chronic obstructive pulmonary disease (COPD). 
Through inhalation, a drug is directly delivered 
to the airways of the lung, which can result in 
high pulmonary drug concentrations and low 
systemic drug concentrations. Therefore, drug 
inhalation is typically associated with high 
pulmonary efficacy and minimal systemic side 
effects (Borghardt et al., 2018).
Due to the complexity of the lung, multiple 
pharmacokinetic (PK) processes exist that are 
specific to the pulmonary environment and 
the inhalation route, making pulmonary PK 
generally distinct and much more complex 
than those of drugs administered via other 
routes (Weber and Hochhaus, 2013).
Edwards et al. (2016) have reported on the 
development of a novel QSAR model (IPRLu) 
that can accurately predict pulmonary 
5 https://www.europeanlung.org/en/projects-and-research/projects/airprom/home
absorption, and act as a potential replacement 
for isolated perfused respiring rat lung model. 
With report good consistency against in vivo 
data, it is suggested that the IPRLu model is a 
suitable tool for investigating lung absorption.
QSAR based approaches have gained 
momentum in the structure-based drug design 
and therapeutic management of infections 
such as M. Tuberculosis, involving a combined 
knowledge of accurate prediction of ligand 
processes with statistically validated models 
derived from the 3D-QSAR approach. Such 
models are particularly used to screen libraries 
of potential synthetic candidates to identify 
docking hits for potential drug molecules to 
address multidrug-resistant tuberculosis. 
(Ahamad et al., 2017)
The diagnosis and classifications of obstructive 
lung diseases are primarily based on global 
lung measurements from pulmonary function 
tests (PFTs). However PFTs are poor predictors 
of patient outcomes for individuals. To address 
these patient-specific issues, medical imaging 
is increasingly being used in diagnosis, 
however the small airways are not visible with 
current imaging techniques. For this reason a 
combined imaging and modelling approach 
is needed to obtain information about the 
respiratory system (Burrowes et al., 2014).
A 5 year European-wide project, AirPROM5 
(Airway Disease Predicting Outcomes through 
Patient Specific Computational Modelling) 
ran between 2011 and 2014 with the aim 
to develop computer and physical models of 
the whole airway system, in particular for the 
investigation of asthma and COPD.
The main focus of the modelling within AirPROM 
was predicting ventilation and the impact 
of pathophysiological changes on resultant 
ventilation and lung function, resulting in 
data and models for both the large and small 
airways. Software has been developed to enable 
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automatic extraction of the morphological 
properties of central airways and lobes from 
patient CT data (Burrowes et al., 2014).
High-resolution computational meshes of 
the central airways and lung surface were 
generated for use in 3D CFD (FRI) simulation 
studies. 1D airway models were generated 
down to the gas exchange level using the 
VFB algorithm. Functional models that predict 
ventilation and impedance within the 1D 
networks have been developed. Correlation of 
model predictions with imaging and measures 
at the mouth will be used for model validation.
The development of better and more accurate 
models will assist in better diagnosis of 
different types of asthma and COPD, allow 
better monitoring of the disease, provide 
tools for more targeted research into disease 
mechanisms, and ultimately assist in the 
development of personalised medicine and 
the matching of appropriate treatments to 
each patient.
The process of modelling requires several 
simplifying assumptions of the system being 
modeled to enable feasibility of solution; 
models will never replicate the complexity 
of reality. However, a model need only be as 
complicated as required to answer a specific 
question.
This will require modellers and clinicians to work 
ever more closely to achieve the shared goal 
of patient-specific clinically relevant multiscale 
models. One of the major hurdles standing in 
the way of computational modelling and its 
clinical use is lack of model validation.
A technique has been developed (Pathmanathan 
and Gray, 2013) to provide a methodical way 
of validation through quantifying the accuracy 
and uncertainty in a pulmonary disease model.
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2 Methodology
2.1 Definition of models and 
methods
IIn this project, the term ‘method’ is used as 
an umbrella term to describe approaches, 
models techniques, assays, experimental or 
computational approaches.
This definition was discussed during the project 
and the definitions were refined as follows:
 • A model (more accurately a ‘tool’) can 
be thought of as a ‘knowledge object’ which 
would be the pivotal point of a database.
 • A method has a purpose and should be 
more descriptive way to practically enact a 
model. A method is what you do with your 
model.
 • With the growing emphasis on human 
relevance, we should talk about the human 
relevance of a model, not a method.
 • A model is used to address a pathology, 
therefore it is important to keep the disease 
in mind.
2.2 Selection and exclusion 
criteria (methods/
publications)
It was agreed that the exclusion criteria should 
not extend to drug effects demonstrating 
receptor expression. Studies that might 
enable the uptake of new in vitro methods 
were retained, so as to ensure a wider 
uptake of in vitro methods, particularly in the 
preclinical sector.
It was also questioned whether the exclusion 
criteria should extend of studies examining 
gene expression in patient populations. It was 
agreed to exclude these studies if they were 
not useful or applied for deeper understanding 
of disease mechanisms, therefore expert 
judgement should decide on their inclusion.
The agreed list of inclusion and exclusion 
criteria are presented in Annex - Table 1.
2.3 Format for extraction of 
models
It was agreed that the extracted data should 
be expressed in the form of selections from 
a series of drop-down boxes. This would 
facilitate easier insertion and management 
of the final inventory. It is assumed that 
interested researchers will use more than one 
data source when conducting their literature 
searches/proposals. The final list of field 
definitions is presented in Annex - Table 2.
2.4 Information sources
With regards to primary literature searches, 
standard multidisciplinary reference databases 
were defined for the retrieval of studies in 
the open literature, as well as a number of 
journals specialising in respiratory diseases, 
references from which should be adequately 
captured in the multidisciplinary databases in 
Annex - Table 3.
A number of relevant organisations were also 
identified as potential sources of information 
for the project, encompassing societies 
involved in research in respiratory diseases, 
commercial entities developing specific non-
animal models for respiratory disease, and 
organisations providing specialised information 
on non-animal models in Annex - Table 4.
It was also proposed to contact various 
research groups, clinical-teaching hospitals 
and commercial laboratories known to be 
Advanced Non-animal Models in Biomedical Research: Respiratory Tract Diseases20
active in the field, with request to provide 
information specific to their areas of research.
It is assumed that there is a significant volume 
of unpublished or yet-to-be published work 
going on in the field and it was therefore 
expected that contacting these relevant 
research groups would provide a better picture 
and improve the quality of the deliverables.
A standard letter was prepared and sent 
to researchers individually by email. Where 
necessary, further personal contacts were 
pursued, for example during attendance of the 
project experts at international conferences.
2.5 Search phrases used
The principal areas of research interest for 
respiratory disease modelling were defined as 
investigations of asthma, chronic obstructive 
pulmonary disease (COPD), cystic fibrosis, 
non-specific fibrosis and lung cancer. These 
diseases were identified as primary keywords 
for the pilot searches.
In order to specify for non-animal models, the 
following modifying keywords were applied.
("in vitro" OR "in silico" OR "ex vivo" OR "3r" 
OR "non animal" OR "animal alternative*" 
OR organoid*) AND ("respirat*" OR "lung" OR 
airway* OR alveol*)).
A conservative (broad) search strategy was 
chosen in order to aim at retaining high 
sensitivity rather than optimising specificity, 
i.e. to minimise the risk of missing potentially 
relevant literature.
Using these search terms, a series of pilot 
searches were carried out in the Web of 
Science (WoS database), with searches 
limited to 2006–2018 publication years. The 
outputs of the pilot searches are shown in 
Annex - Table 5.
Because of the large number of references 
identified in the pilot searches it was agreed 
with the project experts to limit the abstract 
scan initially to non-cancer models to include 
COPD, asthma, and (cystic) fibrosis. A search for 
cancer models was subsequently conducted, 
and the results included here.
Searches were conducted in the databases 
listed in Annex - Table 6.
2.5.1 Abstract retrieval — Non-
cancer references
In total 11,636 unique abstracts were retrieved 
for the non-cancer endpoint models.
Abstracts from each search were retrieved, 
collated to remove duplicates, and uploaded 
to EcoMole’s custom reference manager. 
This is a web-based tool greatly facilitating 
screening and characterisation of literature. All 
necessary information (title, abstract, citation) 
is presented to the reviewer in a structured 
and well-arranged way, as illustrated Figure 1, 
which shows screenshots of a single record in 
the system.
The reference manager allows for various 
types of statistical analysis of the contained 
information, and can be easily sorted and 
filtered according to tags, reviewer, date, etc.
For organisational purposes, full-text 
references selected for further review were 
uploaded and appended to each corresponding 
record in the reference manager.
2.5.2 Abstract retrieval — Cancer 
references
9,421 cancer abstracts were assessed, 
covering the past 5 years. Each abstract was 
reviewed for relevance and were reviewed and 
tagged with reason for acceptance or rejection 
(Figure 2).
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The main reasons for rejection of abstracts 
were that they were not related to respiratory 
disease, or they described studies in vivo or 
using animal cell/tissue, that they did not 
describe a model system, or were not from 
the primary literature. References to non-
receptor mediated drug formulation studies, 
clinical studies and infection studies were also 
reasons to reject.
After abstract screening, the full-text articles 
of accepted references were retrieved from 
subscribed online journal libraries and, similar 
to attached directly to the relevant abstract 
record in the reference manager. Thus, all 
information was collected in an easy to access 
and well-organised database system.
Figure 1: View of single abstract record in reference manager.
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Figure 2: EcoMole reference manager record – abstract view.
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3 Results
6 https://europa.eu/!Tn39yB
3.1 Categorised list of models
The full list of models with their biological 
endpoints studied and measurement 
techniques/technologies used can be found in 
the JRC catalogue6.
When reviewing each full-text paper, a crucial 
determination was whether the model is 
directly relevant (‘stand-alone’) or is supportive 
of other models according to its context of 
use. Models that may be used in comparative 
studies for prediction and/or validation of non-
animal models are also described.
When entering the descriptions into the 
central spreadsheet, the purpose of each 
method/model was detailed, as were the cell 
types used and the culture conditions, and the 
source of the cells.
Using this approach a comprehensive outline 
of each method/model can be provided, with 
direct reference back to the original source 
should more details be needed. Further, it 
allows for easy filtering/searching and parsing 
of the data to allow extended functionality of 
the resulting database. It was envisioned that 
researchers accessing these data online would 
be able to capture and compare alternative 
approaches that use more than one method/
assay, and to allow for a meta-analysis to 
create a more ‘holistic’ approach.
All 11,636 non-cancer and 9,421 cancer 
abstracts captured by the search phrases 
were scanned for relevance using the EcoMole 
Reference Manager. References that were 
clearly relevant were marked and tagged 
(categorised) according to the system outlined 
above. Wherever there were doubts over the 
relevance of a reference, it was marked as 
‘uncertain’ and sent for a full-text review.
A total of 464 non-cancer and 315 cancer 
references were selected from the initial 
abstract screening and sent for full-text review. 
References where relevant models were clearly 
identified from the abstract were marked as 
‘accepted’. Unless there was a clear reason to 
reject the reference based on the abstract text 
(e.g., where the reference is clearly an in vivo 
study) papers were marked as ‘uncertain’ as to 
their relevance, indicating that they may not 
directly fit the inclusion criteria, but nevertheless 
may contain some useful data.
Full-text papers were retrieved for all 
abstracts tagged as ‘accepted’ or ‘uncertain’, 
and these were uploaded to the Reference 
Manager forming the pool of data to be 
reviewed in the next phase. Each full text 
paper was attached as a link to the relevant 
record in the reference manager.
Screening of full text papers involves the 
sequential opening and review of the attached 
full-text papers by two reviewers working 
independently. If the paper contains potentially 
relevant non-animal model data the details 
of the model are extracted to a central 
spreadsheet containing the method/model 
descriptions using the agreed field definitions 
list described above (see Section 2.3).
3.2 Analyses of the retrieved 
data
After all relevant references were reviewed 
and data-extracted, the identified cancer and 
non-cancer models were pooled to a single 
spreadsheet for analysis and the preparation 
of graphics.
In total, 284 unique methods/models were 
extracted across cancer and non-cancer 
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references. The breakdown of models per 
disease area is presented in Figure 3.
Clearly, lung cancer models dominate, followed 
by general disease models, which were not 
focused on a specific disease area, but were 
more concerned with model development. 
Models for asthma are well represented in 
the research literature, followed by models 
concerned with COPD, cystic fibrosis and 
pulmonary fibrosis. Toxicity models and 
‘cigarettes’ were differentiated, as the models 
involving exposure to cigarette smoke model 
general exacerbations. It is must be noted 
that infection-based models were also used 
in exacerbation studies, but in these cases 
directed at investigating a specific disease 
such as asthma, COPD and pulmonary fibrosis, 
and therefore were grouped under these 
disease areas.
Figure 4 shows the breakdown of models by 
disease feature. General exploratory models 
are most prominent and indicate model 
development activities, applicable across 
disease areas. These include, for example, 
the development of microfluidic/chip systems 
which have a wide applicability in respiratory 
disease research.
Annex - Table 7 provides an overview of 
disease features for extracted models mapped 
against the respective disease area.
For asthma, unsurprisingly, inflammation 
(n=12) and airway remodelling (n=11) 
dominate. Models for COPD are more evenly 
spread, but largely deal with those looking 
at inflammation, barrier integrity, mucous 
production and oxidative stress. Models of 
cystic fibrosis cover a range of features. 
For pulmonary fibrosis, the key feature 
investigated is IPF — idiopathic pulmonary 
fibrosis of unknown aetiology.
Lung cancer models primarily look at the 
tumour microenvironment and metastasis, but 
toxicity, cell/tissue viability and drug resistance 
Figure 3: Number of unique non-animal models identified and extracted per disease area.
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studies related to drug development are also 
prominent.
Models looking at respiratory disease in general 
are focused in model development leading 
to wide application across disease areas, 
however infection models and general models 
of inflammation are also well represented.
Figure 5 and related Annex - Table 8 show the 
breakdown of models by category. Cell cultures 
dominate. 2D and 3D culture and co-cultures 
were aggregated as it was not always possible 
to differentiate these by method descriptions. 
Human-derived primary/stem cells and ex 
vivo human tissues are popular model types. 
Microfluidic systems / bioreactors are well 
represented, as are in silico/mathematical 
models. Organoid models are less common 
than expected, indicating that spheroids are 
currently more common in cancer research.
Figure 4: Number of unique models identified and extracted per disease feature.
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Figure 6 represents the main cell/tissue types 
reported. As there are >150 reported types, 
only those cell/tissue types appearing in 3 or 
more models were included in this graphic. 
The full list is provided in Annex - Table 9.
The large number of reported cell types, 
many of which a duplicate descriptions is, 
as discussed below, indicative of a lack of 
descriptive standardisation. Cell and tissue 
types are duplicated, but it was decided that 
these should be reported exactly as described 
in the corresponding literature references.
The A549 epithelia cell line dominates as this 
is a popular and easily accessible choice for 
investigating the efficacy and, mainly, toxicity 
cancer drug candidates. Human bronchial 
epithelial cells (HBEC) are commonly utilised 
in models investigating asthma and COPD. 
‘Other’ cell types are notable in cancer models 
where their identity is not always apparent.
Figure 5: Number of unique models identified and extracted per category.
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Figure 6: Number of methods per tissue/cell type.
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Figure 7 reveals the most common applications 
of extracted models, with each model mapped 
against the respective disease areas shown in 
Annex - Table 10.
Experimental model development leads the 
list, not just in general respiratory disease 
research, but also in lung cancer. Drug 
development and disease therapy are the most 
common applications in lung cancer research. 
Asthma models, as well as those for COPD and 
pulmonary fibrosis are primarily directed at 
the elucidation of disease mechanisms.
Figure 8 and Annex - Table 11 reveal the 
biological endpoints investigated, in total and 
mapped against disease area. Protein / Gene 
/ RNA expressions are the most common 
endpoints investigated across all models. 
Cytokine and inflammatory mediator release 
are characteristic endpoints observed in asthma 
studies, however again these endpoints are 
popular markers and confirmatory indicesand 
outputs in the development of general disease 
models. Viability, cell migration, gene expression 
and metabolism are key endpoints used in in 
vitro lung cancer studies.
Key models identified from each disease area 
are described in Section 4.
Figure 7: Number of unique models identified and extracted per application.
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Figure 8: Number of unique models identified and extracted per biological endpoint.
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4  Discussion
4.1 General observations on 
the extracted models
Despite the shortcomings of animal models 
for disease research, there has been little 
concerted effort to adopt non-animal 
approaches to investigate human diseases, 
in terms of elucidating the mechanism of 
disease and the development of new therapies. 
Consequently, there have been no moves to 
adopt standard methods. Research bodies are 
free to develop their own protocols and internal 
standards. Indeed, a major observation of the 
current project has been that a wide variety 
of approaches are used to investigate similar 
disease aspects.
A very obvious manifestation of this is that, of 
the 284 publications extracted in this current 
snapshot of non-animal biomedical models, 
166 different cell and tissue types have been 
reported. Although the same cell and tissue 
types are used across multiple studies, there is 
no standard use of nomenclature. For example, 
Human Bronchial Epithelial Cells (HBECs) are 
variously decribed as HBEC, cHBEC, HBEC-4, 
saHBEC, dHBE, NHBE, Primary Human NHBE 
or the immortalised HBEC cell line 16HBE14o, 
which is also simply called 16HBE, depending 
on the publication.
The description of methods is also not always 
consistent, for example details of cells and 
tissue specifications are not routinely stated, 
particularly in cancer studies, and sometimes 
the source of cells is not provided. Nevertheless, 
the method descriptions in the identified 
publications are generally sufficient to allow to 
recreation of the methods if required.
In describing the various methods and 
underlying models, elucidation of the disease 
area, features, cell/tissue type, application 
and biological endpoints was typically 
straightforward. Many models investigate 
multiple endpoints, or use multiple cell/tissue 
types — often in combination as co-cultures or 
to cross reference and confirm findings.
Determining the potential of a model was a 
judgement call in the absence of clear potential 
utility in the field. Those models described as 
having ‘high potential to become a disease 
model’ were those that were well-developed 
and have a clear potential, for example 
microfluidic and lung-on-a-chip systems. Some 
indication of potential can be derived from 
the citation indices — the number of times a 
publication has been referenced by others — 
although older publications tend to bias this 
ranking. Nevertheless, it can be seen that the 
most cited recent references are those that 
describe lung-on-a-chip systems.
With regards to throughput, only 5 models 
were indicated as ‘high throughput’, and only 
when this was clearly stated by the authors. 
No ‘high content’ models were detected.
4.2 Main findings
In this study, over 21,000 abstracts were 
scanned for relevant non-animal model of 
respiratory disease. From this, a total of 284 
models were identified as being promising 
candidates for application.
It is worth noting that, in this snapshot, models 
and methods were generally inseparable. The 
vast majority of publications describe a disease 
model and a specific method for utilising that 
model. In only a few cases was the same model 
subjected to different methods (Hill et al., 2016; 
Munye et al., 2017; Schleh et al., 2012). This is 
largely a reflection of the infancy of this field, 
and the fact that non-animal models have 
been developed to investigate a very particular 
disease aspect. Such models — developed to 
focus on a very specific disease feature — 
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are generally not ‘cross-cutting’, i.e. they are 
not considered useful for the investigation of 
another disease area.
For example, in cystic fibrosis research, much 
importance is attached to the cystic fibrosis 
transmembrane conductanc regulator (CFTR). 
This is a protein that serves to maintain the 
balance of salt and water on many surfaces 
in the body, such as the surface of the lung. 
When the protein is dysfunctional — caused by 
a mutation in the CFTR gene — then chloride 
ions becomes ‘trapped’ behind the membrane 
of epithelial cells. The resulting dysregulation 
of epithelial fluid transport in the lung, 
pancreas and other organs means that water 
cannot hydrate the cellular surface, leading to 
the mucus covering the cells becoming thick 
and sticky, manifesting as the symptoms 
associated with cystic fibrosis. Therefore, 
cystic fibrosis models are usually direct at 
investigating the mechanisms behind CFTR 
dysfunction. Such models have limited or no 
application in other disease areas such as 
asthma or pulmonary fibrosis, where different 
disease mechanism are the focus of research.
Models looking at cancer are generally not 
informed by advances in non-cancer models. 
It was noteworthy that ALI cultures are used 
far less frequently than spheroids in cancer 
research, and that spheroids have not become 
widespread tools in non-cancer disease areas.
However, a large number of publications (n=69) 
describe general models, including those in 
the early stages of model development, with 
the aim of reproducibility and with potential 
application across multiple disease areas. 
For example, finding renewable sources of 
human epithelial cells, the recapitulation of 
lung development from human pluripotent 
stem cells (hPSCs), tissue and organoid 
models including novel microfluidic devices 
that mimic the lung microenvironment during 
homeostasis and disease states, and studies 
of respiratory absorption. Such models can 
find wide application in establishing in vivo-
like conditions which can then be manipulated 
and studied for applications including drug 
discovery and development, and achieving a 
level of patient specificity that contributes to 
the development of personalised medicines.
4.2.1 Respiratory disease — 
general
In reviewing the full-text references, a number 
of models were identified that, while not 
describing a specific model of a disease, 
nevertheless represent important baseline, 
supportive models — including standardised/
commercial — that can be developed for wide 
utility for investigating respiratory disease in 
vitro.
Firth and colleagues (Firth et al., 2014) 
describe a method to generate a renewable 
source of human epithelial cells, including 
multiciliated cells that can be used to study 
human respiratory diseases which have 
previously been difficult to study and model 
in vitro. Human induced pluripotent stem cells 
(iPSCs) and derived iPSCs provide an unlimited 
source of cells and also offer the opportunity 
for gene editing and clonal expansion of cells 
for disease modelling. There are several lung 
diseases with a known genetic origin, such as 
cystic fibrosis and primary ciliary dyskinesia 
(PCD) that could potentially be corrected by 
replacement of the defective gene with the 
correct one by gene-editing technology. It is 
hoped that, eventually, patient-specific iPSC 
cells can be used in this model, not only to 
provide a platform for understanding the 
cellular and molecular mechanisms of the 
disease, but to generate a gene-corrected 
transplantable cell type capable of engraftment 
into the lung. This paper has been cited 86 
times since 2014.
Chen et al. (2017) describe the recapitulation 
of lung development from human pluripotent 
stem cells (hPSCs) in three dimensions (3D) 
that can allow deeper insight into human 
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development, as well as the development of 
innovative strategies for disease modelling, 
drug discovery and regenerative medicine. It 
involves the generation of lung bud organoids 
(LBOs) from hPSCs. These organoids contain 
mesoderm and pulmonary endoderm and 
develop into early alveolar structures after 
xenotransplantation, and in Matrigel 3D 
culture. It was shown that LBOs recapitulate 
lung development and may therefore provide 
a method to model lung diseases. Expression 
analysis and structural features indicate that 
the branching structures can reach the second 
trimester of human gestation. Infection in vitro 
with respiratory syncytial virus led to swelling 
and the shedding of infected cells into the 
organoid lumens. A similar outcome has been 
observed in human lungs. Introduction of 
mutations in HPS1, which causes an early-onset 
form pulmonary fibrosis, leads to accumulation 
of extracellular matrix and mesenchymal cells, 
suggesting the potential use of this model for 
the study of fibrotic lung disease in vitro.
McCauley et al. (2017) describe the directed 
differentiation of pluripotent stem cells 
(PSCs) into functional airway epithelial 
cells in response to cyclical modulation of 
developmental signaling pathways. The 
method was used to generate cystic fibrosis 
patient-specific iPSC-derived airway organoids 
showing a defect in forskolin-induced swelling 
that is rescued by gene editing to correct the 
disease mutation. These findings demonstrated 
the rapid generation of airway organoids by 
stage-dependent modulation of Wnt signalling, 
and provide proof-of-principle for the utility of 
these organoids in lung disease modelling.
Tseng et al. (2013) have detailed the assembly 
of a three-dimensional multitype bronchiole 
coculture model using magnetic levitation 
in conjunction with magnetic nanoparticles 
as a means of creating an organised three-
dimensional (3D) coculture. The 3D coculture 
model is assembled from endothelial cells, 
smooth muscle cells (SMCs), fibroblasts, and 
epithelial cells (EpiCs). However, it was noted 
that this group does not appear to have taken 
the models any further than these initial, 
proof-of-concept studies and speculate that 
the development of methods such as 3D 
bioprinting may have overtaken magnetic 
levitation in terms of ease and accessibility.
Pageau et al. (2011) using a 3D culture model, 
discovered that elements of the stroma 
affected the phenotype of HBECs when 
cultured at an ALI. Concentration of type-I 
collagen matrix determined the thickness of 
the overlying epithelium, and incorporation of 
fibroblasts in the model altered the epithelial 
phenotype; such that fetal fibroblasts promoted 
the development of typical epithelium but lung 
cancer-derived fibroblasts promoted more 
invasive behaviour. The authors suggested 
that the effect could be mediated through 
transduction of biomechanical signals from the 
ECM, or through soluble factors secreted by the 
fibroblasts. This study showed the importance 
of the stroma in determining normal and 
pathological conditions, and provides further 
guidance to investigators pursuing 3D culture 
methods as a means of studying these events 
in vitro.
Wilkinson et al. (2016) developed a reproducible 
model system to integrate multiple human 
cell types, including iPSC-derived cells, to 
their correct anatomical location to form lung 
tissue that can be used to model lung diseases 
and perform high throughput drug screening 
for precision medicine. This approach 
uses bioreactor-assisted self-assembly to 
reproduce the anatomy of distal lung alveolar 
sacs by scaffolding mesenchymal cells into 
the interstitial spaces between closely packed, 
biocompatible hydrogel beads in order to 
generate pulmonary-like tissues ready 
for disease modelling. As this method is a 
bottom-up synthesis, it is possible to control 
hydrogel bead composition, size, stiffness, and 
functionalisation as well as number and type(s) 
of cells included. The method can be easily 
scaled in both size and number of organoids, 
potentially bridging the gap between disease 
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modelling and the generation of transplant-
ready tissues.
Morris et al. (2014) have described the 
development of a single scaffold comprising 
of two distinct topographies that recapitulate 
the different microenvironments that airway 
epithelial and fibroblast cells encounter in situ. 
This method shows how matrix development, 
when sympathetic to cellular requirements, 
can provide a relevant 3D in vitro platform 
to investigate important multicellular 
interactions that occur within the airway wall. 
The model cocultures MRC5 fibroblasts and 
CALU3 epithelial cells, with proven fibroblast 
penetration of the microfibre scaffold.
Punde et al. (2014) describe a two-layered 
microfluidic model of protein-induced lung 
inflammation, designed to emphasise the 
role of eosinophil cationic protein (ECP) in 
inflammation, and to demonstrate a dynamic 
migration tool which mimics the physiological 
flow conditions in the body. ECP plays a major 
role in attracting fibrocytes from blood vessels 
to airways. A ‘lung-on-a-chip’ microdevice, it 
mimics the lung microenvironment, providing 
a platform for perfusion culture, with potential 
for use in preclinical studies.
Reus et al. (2014) have demonstrated the 
feasibility of a commercial 3D human airway 
epithelial model (bronchial epithelial model) to 
study respiratory absorption, in particular to 
differentiate between low and high absorption 
of substances. This bronchial epithelial model 
was the commercially available MucilAir™ 
system and can differentiate between 
Personalised disease modelling through iPSC-derived mesenchymal cells grown into organoids
There are currently several methods to develop 
tissue-engineered organoids that replicate the 
organ’s functionality. An important advantage is 
their potential for high throughput drug screening 
to identify targeted therapies 
Wilkinson et al. (2016) generated human lung 
tissue containing self-assembled multiple lung cell 
types that allow cell-cell contact and recapitulation 
of the lung microenvironment.
The organoids formed through the agglomeration 
of cell-coated alginate beads either in a bioreactor 
or in a 96-well plate format and remained viable 
for 2 weeks without degradation.
This system has been found suitable with any cell 
types including iPSC-derived mesenchymal cells 
offering a great potential for use in personalised 
medicine or disease modelling and drug discovery.
Generation and characterisation of 3D pulmonary organoids.
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substances with low and high absorption and 
could be used to predict respiratory transport 
for both safety and efficacy assessment.
Vicens-Zygmunt et al. (2015) describe a 
model that may be useful for investigating cell 
behaviour and phenotypic changes that occur 
during the processes of lung fibrosis and aging, 
as well as for testing different anti-fibrotic 
therapies in vitro. Human lung fibroblasts are 
able to grow into 3D collagenated and stiffened 
matrices under specific conditions. Increasing 
ECM cross-linking via non-enzymatic 
glycation at low ribose concentrations induces 
phenotypic and metabolic changes in the 
fibroblasts, resulting in a mechanical and 
oxidative modified environment which could 
resemble an aging/fibrotic ECM.
Huang et al. (2017) report on the establishment 
and characterisation of SmallAir™, a 
commercial in vitro human small airway 
model using primary small airways human 
cells. SmallAir™ epithelium is tight, with a 
transepithelial electric resistance (TEER) value 
close to that of upper airway epithelia, and 
is therefore ideal for studying permeation 
and drug delivery. This is a powerful tool for 
studying the physiology and function of small 
airways.
Ong et al. (2016) have demonstrated the 
feasibility of generating cultures of primary 
human nasal epithelia resembling in vivo 
epithelium physiology, with highly differentiated 
epithelial cells after 5 weeks in culture at 
the air-liquid interface. The development of 
functional cilia, mucus secretion by goblet 
cells, ability to induce inflammation and viable 
tight junctions represent a promising in vitro 
model for nasal drug delivery studies and 
provides a unique opportunity to study disease 
specific physiological differences of the airway 
epithelium. This model may also form the basis 
for the development of more complex systems 
of in vitro bacterial or viral cell infections and 
inflammation.
Bucchieri et al. (2017) report on the development 
of a robust bronchial mucosal model (the 
epithelial mesenchymal trophic unit or EMTU) 
where cellular outgrowth from bronchial tissue 
might enable development of a mucosal 
structure that recapitulates in vivo tissue 
architecture. Bronchial biopsies taken from 
subjects without lung disease were cultured 
in matrigel until a differentiated, multi-layered 
structure was formed. Structural changes 
observed following cigarette smoke extract 
(CSE) exposure suggest the model could be 
used for drug discovery and preclinical testing, 
especially those targeting airway remodelling.
4.2.2 Lung cancer
Scrutiny of the lung cancer database provided 
several important insights — the rejection 
of almost 95% (n=9,421) of all abstracts 
retrieved indicates the breadth of topic for 
cancer and difficulty in creating precise search 
terms that will only retrieve appropriate non-
animal models with confidence of not missing 
anything.
Almost half of the rejected abstracts were 
categorised as ‘not a model system’, and of 
these, 15% were clinical studies that analysed 
patient samples for RNA or gene expression, 
monitored survival according to gene 
expression, or related protein expression to 
prognosis. 3,876 abstracts were rejected under 
the category ‘not a model’ and of these, 1,099 
employed the A549 cell line. However, despite 
the relevance of this cell line, and its use in 
30% of the accepted abstracts, there were 
many examples of where the use of A549 cells 
could not be classified as a model system. This 
included examples where A549 cells were used 
as one of a panel of cancer cell lines, in a test 
platform for a variety of potentially toxic agents, 
with no differentiation of culture techniques 
for the different cell types, or attempts to 
replicate the relevant microenvironments; or 
using A549 cells for assessment of different 
delivery vehicles like nanoparticles. It was felt 
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that the use of A549 under these conditions 
— cultured under similar conditions to other 
non-respiratory cell lines and used for a 
straightforward readout of toxicity, was not 
taking account of the physiological nature of 
the cells and could therefor not be classified as 
a model of lung disease.
There was evidence of the application of in 
silico approaches in the lung cancer field, with 
over 600 references referring to in silico or 
computational/mathemathical approaches. 
However, only 10 of these could be accepted 
for full text extraction. Reviewing the rejected 
abstracts indicated that the majority of these 
papers were using computational methods to 
examine docking between a possible drug and 
target, or to carry out drug screening studies 
that were not specific for lung cancer, and 
therefore were not included.
We noted that many rejections were due to the 
use of the patient-derived xenografts, where 
human tumour tissue is implanted into an 
animal in order to test different chemotherapy. 
This approach has been discredited recently 
(Ben-David et al., 2017) as alterations in the 
tumours as they progress in vivo removes any 
resemblance to the patient’s disease. However, 
our search returned almost 2,000 references 
with patient-derived xenograft in the title or 
abstract, of which we rejected all but 6.
Despite the continued animal focus in cancer 
research, it would appear that the field 
has benefited from previous work in the 
development of respiratory models in general, 
and that researchers are using these advances 
to create more sophisticated cancer models. 
Our analysis revealed eleven robust models 
with high potential, of which two were in silico/
computational models. Although we might 
have expected more good cancer models, it 
does seem that the advent of microfluidics, 
3-dimensional culture and other approaches 
that are dominating the non-cancer field have 
transferred into cancer research, providing 
these models with an immediate advantage.
Robertson-Tessi et al. (2015) have presented 
a mathematical model of the impact of 
immune cells on tumour cell growth. The 
model derives from experimental and clinical 
data and incorporates several different types 
of T cell, antigen presenting cells as well as 
cytokines. It uses antigenicity and growth rate 
to characterise individual tumours and reveals 
the impact of the adaptive immune response on 
the control of tumour growth, offering insights 
into opportunities for personalised medicine.
Another model (Chen et al., 2018) incorporated 
many salient features of cancer — including 
uncontrolled growth, hypoxia and treatment 
resistance to estimate the effective ability of 
various chemotherapy agents, with a view to 
providing a personalised therapy. This study 
used retrospective analysis of data from 
thirteen people with lung cancer and so it 
seems that a possible progression of this 
mechanistic approach would be to expand 
to offer more effective treatment options for 
people with cancer, based on their specific 
tumour characteristics.
The remaining methods were all in vitro and 
used a variety of cell types and categories, 
according to our classification. Four of these 
models considered tumour microenvironment 
and, interestingly given the method 
developments apparent in the respiratory 
disease database and in disease modelling as 
Our analysis revealed 
eleven robust models 
with high potential, of 
which two were in silico/
computational models
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whole, there was only one model that used the 
microfluidic or chip platform. It is also interesting 
to note that the use of spheroid cultures appears 
to be more common for cancer models, with 
19 confirmed references compared to just 6 for 
non-cancer database. Application of spheroid 
cultures for cancer research have been known 
for over 30 years (Sutherland and Durand, 
1984) and this platform is particularly relevant 
for cancer because these 3D models exhibit 
physiologically relevant cell-cell and cell-matrix 
interactions, gene expression and the structural 
complexity that reflect the tumour.
It is worth pointing out the commercial 
availability of a lung cancer model — the 
OncoCilAir™ from Epithelix — featured in only 5 
abstract hits in the database, despite originating 
in 2015. The advantage of this would be the 
reproducibility that is implied with a commercial 
model and which is of utmost importance 
to deal with emerging issues with in vitro 
research beyond those that can be addressed 
with good cell culture practice (Pamies, 2018). 
We categorised one of the OncoCilAir™ papers 
(Benainous et al., 2018) as reflective of a good 
model. This model combines different cell 
types, using human primary cells and exploits 
culture at the air-liquid interface to generate a 
physiologically accurate model of the airways, 
with incorporation of adenocarcinoma cells to 
enable tumour formation. Analysis revealed 
that the model recapitulates the invasive nature 
of tumour cells into surrounding tissue and that 
this potentially provides a useful and relevant 
platform for drug screening. We would have 
expected to see more broad use of this model, 
and can only speculate that the comparative 
costs of buying in ready-made cultures like this 
are preventing its use more widely.
It was felt that one of the ‘good’ in vitro 
models was particularly suitable for disease 
development and the remainder were more 
appropriate for drug discovery. This model 
used a human lung carcinoma cell line cultured 
with cytokine-induced killer cells derived from 
human peripheral blood monocytes (Chen 
et al., 2018). Interestingly, this paper also 
included an in vivo element that showed that 
the use of cytokine-induced killer cells, which 
were effective at reducing tumour in vitro, also 
reduced tumour volume in mouse models.
Other important cancer models (Hassell 
et al., 2017; Wu et al., 2018; Wang et al., 
2018; Yang et al., 2018; Alonso-Nocelo et 
al., 2016; Solomon et al., 2016; Yamazoe et 
al., 2016) were all suited to drug screening 
and discovery through mimicking of tumour 
microenvironments. As expected, tumours 
are not a ‘normal’ tissue and thus capturing 
the hypoxic, proliferative, pro-angiogenic 
environment is of the greatest importance 
for modelling cancer. It would appear that, 
despite broad parallels with methodological 
approaches for both cancer and non-cancer 
models (air-liquid interface, co-culture, etc.), 
the significant differences in the cell types 
required to recapitulate the disease phenotype 
(T cells, antigen presenting cells, carcinoma 
cells) and the specifics needed to recapitulate 
the tumour microenvironment prevent any 
significant cross-over between the two.
Correia et al. (2017) described a model of 
bronchial dysplasia, the precursor lesion 
to squamous lung cancer. Earliest stages 
of bronchial epithelial carcinogenesis were 
modelled using using nonvirally immortalised 
human bronchial epithelial cells with a stable 
karyotype and an intact p53 signalling response/
pathway. The model recapitulates human 
bronchial dysplasia in vitro. SOX2 deregulation 
drives dysplasia, and loss of TP53 is a co-
operating genetic event that potentiates the 
dysplastic phenotype. Deregulated SOX2 alters 
critical genes implicated in hallmarks of cancer 
progression. Targeted inhibition of AKT prevents 
the initiation of the dysplastic phenotype.
Yang et al. (2018) have developed an 
electrospinning nanofiber membrane-
supported lung-on-a-chip microdevice for 
anti-cancer drug testing taking the alveolar 
microenvironment as a model. Gefitinib, an 
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epidermal growth factor receptor (EGFR)-
targeted anti-tumour drug, was tested in 
on-chip cell culture and co-culture of human 
non-small cell lung cancer cells (A549) and 
human fetal lung fibroblasts (HFL1). This 
simple, effective, and easy to operate system 
is expected to find important applications in 
personalised treatment of lung tumors and to 
play a potential role in other clinical treatments 
and tissue engineering.
Han and Hsu (2016) co-cultured mesenchymal 
stem cells (MSCs) and human non-small 
cell lung carcinoma cells (A549) on a thin 
biomaterial-based substratum (hyaluronan-
grafted chitosan, CS-HA; similar to 2 µm), which 
self-organised into the 3D tumour co-spheroids 
with core-shell structure. Tumorigenicity 
observed in a zebra fish xenotransplantation 
model was consistent with that observed 
in vitro, suggesting that this 3D co-culture 
platform for cancer cells and MSCs may be 
a convenient tool for studying the cell-cell 
interaction in a tumour-like microenvironment 
and potentially for cancer drug testing.
4.2.3 Asthma
3,883 abstracts containing the keyword asthma 
were reviewed. Of these, 157 were selected for 
full-text review. The main reasons for rejection 
of asthma abstracts were that they described 
studies in vivo or using animal cell/tissue, that 
they did not describe a model system, or were 
not primary literature. After full-text review, 
41 distinct references describing non-animal 
models of asthma remained.
Lung-on-chip to simulate tumour microenvironment
Microfluidic chip technology can be used to simulate 
the physiological and pathological conditions of 
human tissue and organs.
Yang et al. (2018) developed a simple lung tumor-
on-a-chip with a an electrospinning nanofiber 
membrane as a substrate of the chip and the 
cell 3D culture scaffold. This model simulates 
the alveolar microenvironment and the tumour 
microenvironment alveolar biochemical factors, 
especially in the respiratory membrane.
On this chip, they grown 3D cell culture and co-
culture of the human lung non-small cell lung 
cancer cell line A549 and human fetal lung 
fibroblast HFL1 cells, and tested the effects of the 
gefitinib, an EGFR-targeted anti-tumor drug
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The most important models identified include 
that of Chin et al. (2012) who describe the 
modelling of the mechanical properties of 
asthmatic airway smooth muscle using human 
ASM strips to study force induced by electric 
field stimulation (EFS) in situ. Mechanical 
properties of human ASM from asthmatic 
and nonasthmatic subjects were shown to 
be comparable allowing the modelling of 
bronchodilation in asthmatic subjects.
Freishtat et al. (2011) have developed a 
proposed model for airway epithelial-derived 
inflammation in asthma; an adapted in vitro 
epithelial injury model that allows for the 
study of epithelial repair processes in the lung. 
Normal and asthmatic primary differentiated 
human airway (i.e., bronchial) epithelia can be 
grown in 12-well plates on collagen-coated 
Transwell membrane inserts at an air-liquid 
interface. This allows for the measurement of 
inflammatory (i.e., IL-1b, IL-6, IL-10, and IL-13) 
and fibrogenic (i.e., transforming growth factor 
[TGF]-b1) cytokines in apical and basolateral 
secretions by flow cytometry. These cytokines 
have a prominent role in asthmatic inflammation 
and remodelling. The cultures were wounded by 
scraping and cytokine release and regeneration 
was assessed for asthmatic and non-asthmatic 
cultures. The asthmatic epithelial models were 
less able to regenerate and secreted more pro-
inflammatory and fibrogenic mediators. This 
model demonstrated the role of the epithelium 
in the asthmatic phenotype and showed the 
positive effects of glucocorticoid treatment 
indicating possible utility for drug screening.
Hackett et al. (2011) showed that ALI cultures 
can be used to investigate and compare many 
of the phenotypic differences within the airway 
epithelium of asthmatic and non-asthmatic 
patients. In this model, asthmatic-derived ALI 
cultures respond with an increased expression 
of inflammatory mediators IL-6, IL-8, and 
GM-CSF to both environmental (infection 
with RSV, exposure to air pollution) and 
nonspecific mechanical damage, compared 
with nonasthmatic ALI cultures.
Hill et al. (2014) developed a theoretical 
biochemical/cell-free assay of mucus solids 
concentration as a potential biomarker for 
airways disease. Reference ranges for mucus 
solids concentration in healthy and disease 
states were derived from clinically-collected 
sputum samples, and mucus harvested from 
primary human bronchial epithelial (HBE) cell 
cultures. Analysis of the datasets provided 
a comprehensive assessment of barrier 
(diffusivity) and transport (viscoelasticity) 
functions of HBE mucus versus concentration. 
It was shown that clearance and barrier 
functions of mucus scale with mucus solids, 
providing a theoretical and practical basis 
for the use of mucus solids concentration as 
a clinical marker for phenotyping subjects 
with airway disease, and for the outcomes of 
clinical trials.
Gras et al. (2012) reported the development 
of an ex vivo model of severe asthma using 
reconstituted human bronchial epithelium. 
Human bronchial epithelial cells (HBEC) 
derived from endobronchial biopsy specimens 
of patients with mild and severe asthma 
maintained in culture in an air-liquid interface 
can reproduce a fully differentiated airway 
epithelium. This facilitates the practical study 
of features of airway remodelling, epithelial 
and subepithelial layers, as well as mucus 
production. Resulting differentiated epithelia 
could then be analysed for morphology and 
function based on ultrastructural analysis, 
IL-8 release, lipoxin A(4) generation, mucin 
production, and lipoxygenase gene expression.
Nesmith et al. (2014) have developed a 
model of human airway musculature on 
a chip, presenting an in vitro model of 
allergic asthmatic bronchoconstriction and 
bronchodilation. This system can mimic 
the structural architecture and functional 
hallmarks of contraction of BSM on a chip, 
which can be used as a practical model of 
responses to novel drug treatments.
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4.2.4 Chronic obstructive 
pulmonary disease (COPD)
A total of 1,359 abstracts containing the 
keyword COPD were scanned for relevance, 
with 97 references marked for full-text review. 
After full-text review, 27 distinct references 
describing non-animal models of COPD 
remained. Rejection of abstracts was on the 
same basis as described above (in vivo studies, 
use of animal tissues/cells, etc.)
Key models identified include:
 • Sul et al. (2018) developed computational 
fluid dynamics (CFD) model of airflows for 
steady expiration to investigate how terminal 
flows affect airflow patterns in respiratory 
airways healthy and diseased lung.
 • Gohy et al. (2015) showed that epithelial-
mesenchymal transition (EMT)-related de-
differentiation of the epithelium occurs in 
COPD conducting airways and correlates 
with peribronchial fibrosis and with airflow 
limitation. These changes are recapitulated in 
vitro, during ALI-driven re-differentiation of the 
epithelium, at least in part as a consequence 
of TGF-β signalling. EMT therefore is an 
important component of airway disease 
in COPD and targeting it could reveal an 
attractive therapeutic strategy to restore 
epithelial barrier and integrity.
Wagner et al. (2014) demonstrated that 
cadaveric lungs from individuals with 
chronic lung diseases such as COPD can be 
appropriately decellularised and recellularised 
to retain characteristic histological 
architecture and ECM reflecting either normal 
or COPD, particularly emphysematous, origin. 
Inoculation of human bronchial epithelial cells, 
endothelial progenitor cells, bone marrow-
derived mesenchymal stem cells, and lung 
fibroblasts via airway or vascular routes into 
small, excised segments of the decellularised 
lungs demonstrated that normal lung scaffolds 
robustly supported initial engraftment and 
growth of each cell type for up to one month. 
In contrast, despite initial binding, all cell types 
inoculated into decellularised emphysematous 
lungs did not survive beyond one week.
4.2.5 Pulmonary fibrosis
A total of 1,093 abstracts containing the 
keyword ‘pulmonary fibrosis’ were scanned for 
relevance, with 46 references marked for full-
text review. After full-text review, 21 references 
describing non-animal models remained. A 
number of key models were identified.
He et al. (2017) have developed a microfluidic 
co-culture device as a human disease model 
of pulmonary fibrosis. The device can monitor 
the fibrotic process by looking at epithelial-
interstitial cell communication. Epithelial cells, 
fibroblasts, and macrophages can be cultured in 
parallel channels to mimic the in vivo epithelial-
interstitial tissue interface of the lung. Epithelial 
cells formed an intact monolayer lining the 
fibronectin-coated channel, representing the 
alveolar space and alveolar wall. Culture 
medium treated with BLM is introduced to induce 
injury and stimulate paracrine communication 
between the cell types. The epithelium sends 
paracrine signals to activate interstitial cells, 
resulting in the migration of fibroblast and 
inflammatory cells with a subsequent increase 
in collagen I deposition at the ECM. The study 
confirms that epithelial injury is a source of 
epithelial/fibroblastic cross-talk during BLM-
induced fibrosis, indicating that this co-culture 
system recapitulates the critical pathological 
changes characteristic of pulmonary fibrosis.
Mikami et al. (2016) report on the development 
of the gel contraction assay as an in vitro 
model of contractility, which is a characteristic 
function of fibroblasts that contributes to 
wound repair and fibrosis. Cultured A549 
human lung epithelial cells were induced 
to epithelial-mesenchymal transition (EMT) 
by TNF-α and TGF-β1. Type I collagen gels 
containing mesenchymal cells that underwent 
EMT were reduced in size, indicating contraction 
of those cells. It was thus suggested that the 
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gel contraction assay should be considered 
as an extended in vitro assay to evaluate 
contractility, as mesenchymal cells that 
underwent EMT are thought to contribute to 
the pathogenesis of fibrosis.
Rajangam et al. (2016) claimed to have 
developed the first biomimetic 3D in vitro 
fibrosis model. Three-dimensional cell masses 
(3DCMs) of human adipose-derived stem cells 
(hASCs) were shown to be transformed into 
activated myofibroblasts by growing them on a 
MBP-FGF2-immobilised substrate. The hypoxic 
microenvironment created in the interior of 
the 3D cell masses during the early stages 
of culture leads to activation and synthesis 
of TGF-β1. The gene expression of fibrosis-
related molecules (TGF-β1, a-smooth muscle 
actin (aSMA), and collagen type I) were shown 
to be upregulated in the cell masses. Over time, 
overexpression of TGF-β1 led to differentiation 
of hASCs into activated myofibroblasts, which 
deposit excessive collagen type I and are 
characterised by aSMA expression. This model 
might therefore be used to study the common 
mechanism of fibrosis, which could then be 
targeted for the development of broad range 
antifibrotic compounds.
Roach et al. (2018) present an ex vivo human 
lung parenchymal model of fibrogenesis which 
recapitulates the pro-fibrotic events evident 
in idiopathic pulmonary fibrosis (IPF). 2mm3 
sections of human lung parenchyma were 
cultured for in medium containing TGFβ1. 
After 7 days a fibrosis-associated increased 
expression of ECM proteins (Collagens I 
and III), and fibroblast-specifc protein were 
demonstrated by immunohistochemical 
staining. The involvement of KCa3.1 ion 
channels — which play a key role in TGFβ1-
dependent pro-fbrotic responses in human 
lung myofbroblasts — was demonstrated by 
the addition of senicapoc, a selective KCa3.1 
blocker.
The authors contend that this model has 
potential to simplify and accelerate the 
evaluation of therapeutic targets for human 
lung fibrosis, and may also provide insights 
into the mechanism of drug action.
Surolia et al. (2017) explored the utility of 
3D primary cell culture systems in creating 
an ex vivo model of the IPF lung. The authors 
generated ‘pulmospheres’ from lung biopsies 
from 20 IPF patients and 9 control subjects. 
These are 3D clusters of cells (spheroids) 
derived exclusively from primary lung tissue 
cultures in vitro, and including all cell types 
found in the human lung. Control pulmospheres 
were positive for surfactant protein C (a 
marker for epithelial type II cells), CD31 
(endothelial cells), CD11b (macrophages), 
and α smooth muscle actin (α-SMA) (vascular 
smooth muscle cells and myofibroblasts). All 
these various types of cells were embedded in 
extracellular matrix (ECM) proteins — collagen 
type I, fibronectin-EDA, and collagen type IV. 
The IPF pulmospheres also demonstrated 
presence of α-SMA-positive, SPC-positive, 
CD31-positive, and CD11b-positive cells. 
Immunofluorescence staining demonstrated 
enhanced staining for ECM proteins, such as 
collagen type I, fibronectin-EDA, and collagen 
IV. These features of lung pulmospheres 
reflect the in vivo situation where cells are 
supported by surrounding ECM proteins. 
As these pulmospheres simulate the lung 
microenvironment, they may find utility as 
a predictive model to assess the efficacy of 
antifibrotic drugs in IPF patients.
4.2.6 Cystic fibrosis
A total of 1,651 abstracts were retrieved, with 
72 references marked for full-text review, 
from which 25 models were extracted.
Sears et al. (2015) demonstrate that culturing 
well-differentiated HAE cells in a circular track 
is a simple and reproducible method to study 
mucociliary transport (MCT) in vitro. Normal 
mucociliary clearance (MCC) is essential for 
maintaining a healthy respiratory system, and 
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impaired MCC is a feature of many airway 
diseases, including cystic fibrosis. Millicell 
cell culture inserts are modified to make MCT 
devices (MCTD). To create MCTDs, a plastic 
central cylinder (15-mm outer diameter) is 
glued with silicone sealant onto the membrane 
in the center of the insert, and coated with 
collagen. Cells from a significant fraction of 
donors are capable of coordinating their ciliary 
motility to produce mucus flow in a defined 
pattern, and, once established, this transport 
is stable for the lifetime of the culture. Using 
this device, it is possible to make repeated 
measures of the overall speed of transport, as 
well as many of the individual components of 
MCC, including cilia beat frequency (CBF), fluid 
heights, mucus concentration and composition, 
etc. The device is amenable to a wide range 
of in vitro manipulations, as illustrated by the 
studies presented above, and will be useful 
in the development and testing of therapies 
targeting MCC. The device will also be useful 
to investigate the mechanisms responsible 
for the coordination of ciliary motility and 
determine the effects of diseases including 
cystic fibrosis on MCT.
Pranke et al. (2017) assessed CFTR function 
in vivo via nasal potential difference (NPD) 
and in human nasal epithelial (HNE) cultures. 
HNE cells were sampled by nasal brushing of 
both nostrils after local visualisation of the 
nasal mucosa and HBE cells were isolated 
from bronchial explants. Freshly isolated HBE 
or HNE cells were then seeded on porous 
flters with culture medium and cultured in 
an air-liquid interface for 3–4 weeks. The 
level of CFTR correction in HNE cultures 
significantly correlated with the FEV1(Forced 
Expiratory Volume in the first second) change 
at 6 months in 8 patients treated with CFTR 
modulators. Importantly, this study correlated 
an in vitro readout (chloride channel activity) 
with in vivo data (lung function through FEV1 
measurement) from the same patient to show 
the positive impact of the Vertex CFTR modifier 
Ex vivo human lung parenchymal model of fibrogenesis
Pulmonary fibrosis is a severe respiratory 
disease in which scars are formed in the lung 
tissues, as a result of the accumulation of excess 
fibrous connective tissue.
Roach et al. (2018) have used ex vivo human 
tissue obtained from lung of patients undergoing 
lung resection for carcinoma to investigate their 
hypothesis that TGFβ1-induced pro-fibrotic 
structural responses are inhibited by a selective 
KCa3.1 blocker.
This model is based on ex vivo human lung 
parenchyma cultured for 7 days in serum-free 
medium containing TGFβ1 and essential nutrients.
By examining nuclear morphology, tissue necrosis, 
metabolic activity and RNA quality, the authors 
assessed the lung tissue viability and response.
Magnified H&E-stained images of tissue embedded on day 
0 or after culture for 7 days in serum-free medium form the 
same donor shows preserved nuclear morphology with no 
sign of nuclear fragmentation.
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drugs. This study therefore provides the first 
evidence that correction of CFTR function by 
CFTR modulators in HNE cell cultures, measured 
by quantification of the CFTR-mediated 
Cl− secretion, may be a valuable surrogate 
biomarker to predict clinical response and 
indicate respiratory improvement.
Darch et al. (2017) have developed an in 
vitro model based on chronic Pseudomonas 
aeruginosa infection of the CF lung. This 
model utilises a synthetic sputum medium 
that readily promotes the formation of P. 
aeruginosa aggregates with sizes similar 
to those observed in human CF lung tissue. 
They have used high-resolution imaging, to 
elucidate the life history of P. aeruginosa and 
the mechanisms that it employs to tolerate 
antimicrobials, specifically, bacteriophages. 
The initial goal of this study was to develop 
a model that recapitulates important aspects 
of in vivo bacterial growth and physiology 
and then use this model to provide insights 
into how microbes respond to antimicrobial 
therapies. The majority of people with CF will 
die because of lung infections, and around half 
of all people with CF are chronically infected 
with P. aeruginosa.
Ahmadi et al. (2017) adapted a fluorescence 
plate reader assay of apical CFTR-mediated 
chloride conductance to enable profiling of 
a selection of modulators on primary nasal 
epithelial cultures derived from patients 
bearing different CFTR mutations. This 
platform faithfully recapitulates patient-
specific responses previously observed in the 
Ussing chamber assay. In proof of concept 
studies, they also validated the use of this 
platform in measuring drug responses in lung 
cultures differentiated from CF iPS cells. This 
medium throughput assay of CFTR activity 
has the potential to stratify CF patient-
specific responses to approved drugs and 
investigational compounds in vitro in primary 
and iPS cell-derived airway cultures. The 
longer-term goal is to optimise the apical 
chloride conductance (ACC) assay so that large 
chemical libraries can be screened on patient-
derived nasal cultures and iPS cell-derived 
epithelium.
Guimbellot et al. (2017) and Brewington et 
al. (2018) both describe the development of 
‘nasospheroids’ derived from nasal epithelial 
cells (NEC) from CF and healthy patients. 
NECs are centrifuged in medium, forming 
pellets containing sheets of epithelia. Pellets 
are then seeded onto a collagen-coated 
dishes containing epithelial growth medium. 
Nasospheroids form spontaneously within 2–5 
days and were shown to exhibit key features 
of mature respiratory epithelia including 
cilia, mucus secretion, and separate apical/
basolateral membranes supporting luminal 
fluid secretion. CFTR activity can be measured 
by viewing changes in cross-sectional area 
using confocal microscopy.
Nasospheroids derived from healthy patients 
(active CFTR-mediated ion and fluid movement) 
show a reduction in cross-sectional area, 
whereas no such changes were observed in 
CF spheroids. Nasospheroids from F508del 
CF homozygotes that treated withlumacaftor 
and ivacaftor did show a significant reduction 
in cross-sectional area, indicating therapeutic 
efectiveness in restoring CFTR function 
(Guimbellot et al., 2017). When stimulated 
with forskolin/IBMX — which rasie the levels 
of cyclic AMP, spheroids were seen to swell in 
the presence of functional CFTR, and shrink 
in its absence (Brewington et al., 2018). 
Nasospheroids therefore show potential for the 
understanding of rare CFTR mutations. These 
spheroids are easily acquired, personalised 
and accurately represent the architecture and 
functions of airway tissues.
4.2.7 Other disease areas
After full-text review, 5 toxicity models, 
3 related specifically to cigarette smoke 
exposure, 3 models of allergic rhinitis and one 
of tuberculosis were also included.
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Park et al. (2016) demonstrated that, by 
means of minimally invasive nasal brushing, 
it is possible to harvest nasal cytology 
specimens in sufficient amounts for ALI 
culture of nasal epithelial cells in patients with 
allergic rhinitis (AR). ALI culture of ARNE cells 
showed distinguishing histologic morphologies 
and physiologic features compared to NHNE 
cells, and cultured ARNE cells preserved the 
pathologic conditions occurring in the nasal 
epithelium of AR patients. Such findings will 
expedite the clinical application of in vitro 
studies to predict the molecular mechanisms 
of AR and the potential role of the epithelium 
in allergic diseases.
Mathis et al. ( 2015) followed up on their earlier 
work comparing changes in gene expression 
in response cigarette smoke exposure to look 
at microRNA analysis of human organotypic 
bronchial epithelial cultures. They identified 
several cellular pathways that were affected 
by cigarette smoke exposure and that these 
could be both dose- and time-dependent. They 
propose that their model is useful in terms of 
adhering to the principles of Tox217 and so 
this approach may be more vaild for inhalation 
toxicity testing, but could be adapted for 
disease modelling.
4.3 Future developments
The last decade has seen significant progress 
in the develpment of new in vitro models of 
the human lung. In vitro (and ex vivo) model 
systems have enormous potential to improve 
our understanding of lung biology, such as 
investigating the effect of growth factors, 
oxygen availability, cell development and 
differentiation, and other factors that control 
cell fate and tissue morphology.
Nevertheless, there are many biological 
questions and technical challenges yet to be 
overcome.
7 https://tox21.gov/
As an example, the potential of human 
pluripotent stem cells (hPSC) has led to 
methods that promote differentiation of 
multiple lung epithelial cell types at the same 
time. However, methods for deriving lung 
tissue from hPSCs use different combinations 
of growth factors, leading to variations in the 
derived cell populations. The adoption of a 
more systematic approach should elucidate 
the mechanisms that control differentiation 
of specific cell lineages in vitro, allowing more 
controlled tissue engineering and translational 
applications of hPSC (Miller and Spence, 2017).
A notable disadvantage of current in vitro/ex 
vivo methods is that they cannot integrate 
the proximal (airway) and distal (alveolar) 
compartments of the lung into a single, 
reproducible model. The interaction between 
these distinct anatomical compartments 
and their unique cell types have important 
roles in lung development, homeostasis, and 
pathogenesis that cannot yet be captured 
outside of an organism.
The development of unifying models brings 
additional technical challenges, such as the 
need to grow different cells and tissues in 
different media. For example, epithelial tissues 
grow more readily in laminin-rich matrices 
(e.g., Matrigel), whereas endothelial and 
mesenchymal cells tend to favour collagen 
matrices (Miller and Spence, 2017). However 
these challenges are already being overcome, 
notably in the development of modular 
‘human-on-a-chip systems’. These already 
exist for toxicity testing (Abaci and Shuler, 
2015; Prantil-Baun et al., 2018) and could 
be adapted for disease modelling. The future 
should see an entire respiratory tract on a 
chip, incorporating nasal, upper airways and 
lower airways chips, each comprising different, 
relevant cell types.
Matrix stiffness affects cellular function and 
ongoing developments in the use of scaffolds 
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in cell culture — particularly hydrogels 
— offer the prospect of growing complex 
tissue / organoids in a well-defined physical 
environment, allowing precise regulation of cell 
fate and tissue homeostasis, and mimicking of 
the extracellular matrix (ECM) (Enemchukwu 
et al., 2015). This should allow detailed study 
of the influence of ECM and other physical 
parameters such as stiffness and stretch, 
which are critically important factors in lung 
development, and which may exert influence 
on the progression to disease states (Miller 
and Spence, 2017).
Models looking at environmental or cigarette 
smoke exposure, as designed for inhalational 
toxicity studies, should attempt to adhere to 
Tox21 principles, but allowing for extension 
of resulting methods to look at disease 
modelling involving cigarette smoke induced 
lung damage and disease progression, and 
the impact of environmental pollution on, for 
example, diseases like asthma.
Undoubtably, if we are to describe the state-
of-the-art in respiratory disease research, 
then the development of organoids and 
lung-on-a-chip technologies offer the best 
potential models for investigating disease 
mechanisms and potential therapies, including 
drug development. Nevertheless, their use as 
disease surrogates requires standardisation of 
all aspects of culture.
Lung organoid culture systems are ripe 
for development in disease modelling and 
treatment. They offer the ability to investigate 
the functions of various cells types in distinct 
regions of lung tissue, while also allowing the 
monitoring of their behaviour in different micro-
environments. In particular, the generation of 
patient-derived organoids from biopsies will 
provide powerful research tools for a wide 
range of translational and medical approaches, 
such as drug efficacy and toxicity studies.
The development of lung-on-a-chip microdevices 
represents a major advance from traditional 
cell culture and offer the prospect of integrating 
microfluidics and microfabrication technologies 
with cultured living cells to reconstitute the 
most relevant architecture and functions of 
living human organs. It is thus encouraging to 
see that such devices are well represented by 
22 seperate methods published since 2015.
These devices are innovating to the extent that 
there now exists a “breathing lung-on-a-chip” 
microdevice which recreates physiological 
breathing movements by applying a vacuum 
to the side chambers and causing mechanical 
stretching of the poly(dimethylsiloxane) 
membrane forming the alveolar-capillary 
barrier (Huh, 2015).
Future developments in this area require the 
nurturing of a multidisciplinary approach, 
requiring cooperation between disease-
focused biologists, bioengineers and 
mathematical modellers, so as to develop an 
all-encompassing understanding of how the 
structural environment of the lung relates to 
normal and diseases states.
Organoids and lung-on-
a-chip technologies offer 
the best potential models 
for investigating disease 
mechanisms and potential 
therapies
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5 Conclusions
This review of non-animal models and methods 
for respiratory disease research shows that we 
are on the cusp of an expansion of sophisticated 
methods to recapitulate in vivo human lung 
conditions, allowing us to target specific 
endpoints for disease research and to greatly 
enhance the development of therapeutics for 
major lung disease, including cancer, asthma, 
chronic obsructive pulmonary  disease (COPD) 
and pulmonary and cystic fibrosis.
An important output of this study is a detailed 
catalogue (database) of models and methods 
that has been made publicly available via 
JRC Data catalogue. Every effort is needed 
to disseminate this inventory as widely as 
possible to maximise its utility and impact.
Biomedical researchers looking to find non-
animal models in a particular disease area, 
national committees (ethics, funding), and 
teaching institutions (universities). can all 
benefit from the results of this study.
Other key stakeholder groups include Member 
State National Committees under Article 49 
of Directive 2010/63/EU on the protection 
of animals used for scientific purposes and 
the European Network of Research Ethics 
Committees (EUREC).
Each stakeholder group will likely approach 
this knowledge source differently, for example 
funding committees may want to have a 
simple overview of existing non-animal models 
for a specific disease type. Researchers would 
require more detailed information on, for 
example, cell types utilised and specific details 
of the methods used.
A catalogue of non-animal biomedical models 
can offer added benefit here by allowing greater 
search capacity for accessing all models using a 
specific cell type. In this way the ‘noise’ of larger, 
general, database can be removed, reducing the 
time spent sifting through irrelevant references. 
As it stands, the use of citation indices extracted 
here could be used as an approximate marker 
of model acceptance by other researchers.
By promoting the catalogue as a uniform 
platform useful for researchers, evaluators 
and policymakers, it could be the focus of 
concerted efforts to satisfy the Three Rs in 
biomedical research.
Crucially, there is a need for more research 
funding to promote and develop these methods. 
National bodies and competent authorities 
have a role here — by cross-checking research 
applications against this database they will 
have a powerful tool to help assess whether 
proposals for animal-based research are truly 
compliant with the Directive when providing 
funding. In addition it contributes to the 
growing wish of the public at large to reduce 
and eventually eliminate the need for animal 
models of biomedical research.
In summary, a number of key areas for 
resolution have been identified in order 
to promote the uptake, development and 
standardisation of non-animal models for 
respiratory disease research:
Conclusions 49
Standard operating procedures (SOP) 
for model generation and testing will be 
essential and should be encouraged.
Define where models could be used — 
if models are better suited to address 
specific research questions (eg different 
diseases, specific pathologies, certain outputs) 
then model developers should indicate how 
their model is suitable for which aspect.
Lung-on-chip models will continue to grow 
in use as these can provide the ability 
to mimic breathing and allow realistic 
exposure to allergens and noxious particles 
such as cigarette smoke and infectious agents. 
Lung-on-a-chip models also enable 
real-time analysis of readily accessible 
biomarkers. However, these models need 
to overcome use of plastic substrates as this 
is not representative of human tissue.
Promote more effective cross-talk between 
the fields of oncology and respiratory 
diseases — this will be essential for 
further development of organoid models.
Organoid models are already proving 
invaluable for the analysis of cell-cell and 
cell-matrix interactions in lung cancer 
models and these could be equally valid for 
the wider respiratory disease field.
Organoid models have proven useful in 
cystic fibrosis research — where increased 
swelling is used to represent enhanced 
mucus production. Functional readouts from 
organoid models could also be applied for 
investigation of other inflammatory and 
infectious lung conditions.
Precision cut lung slice (PCLS) models 
are probably the best model in terms of 
representation of the multiple different 
cell types, tissue architecture and physiological 
response of human lung tissue. However, their 
use is restricted due to tissue access and this 
situation is unlikely to improve in the future, 
particularly for conditions such as asthma 
and cystic fibrosis. 
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Table 1: Non.animal respiratory disease models - Objective criteria for retaining or excluding models from 
consideration.
Inclusion criteria Exclusion criteria
Review question: Define the suitability of a non-animal model for respiratory disease research
Type of method
The method does not require the use of live vertebrate 
animals, nor does it require the destruction of life each 
time it is performed (e.g specifically for the purpose 
of tissue extraction from multiple living entities).
This includes:
 • in vitro methods (including cell cultures, organoids);
 • ex vivo methods using human tissues;
 • in silico methods (e.g., modelling of air flow 
patterns in lung).
Studies that examine the effects of stimulation/drug 
exposure on receptor expression (excluded at first).
The method depends on the use of live vertebrate 
animals for its performance.
Ex vivo methods using tissues derived from vertebrate 
animals.
Human genome studies focused entirely on patient 
groups.
Drug effects on cell cultures, where the culture model 
is poorly described, or appears to use submerged 
monocultures, and where the overall focus of 
the study is to look at DRUG effects, not disease 
mechanisms or model development.
Mechanistic studies that are not developing models 
but are looking at/manipulating individual factors in 
a disease and are not comparing to a healthy system 
(i.e., not modelling disease).
Studies that employ immune cells (T cells, B cells, 
eosinophils, neutrophils) in isolation (i.e., without a 
model). These studies are not considering their wider 
role, just looking at features/responses/profiles of the 
immune cells.
(Note: In order to promote wider uptake of in vitro 
methods, particularly in the preclinical sector, JRC 
advised to retain all studies that might enable the 
uptake of new in vitro methods. Therefore such 
studies are brought under inclusion criteria).
Studies that appear to examine the effects of 
stimulation with a drug/ stimulus/ pathogen/ receptor 
agonist without considering the baseline response 
(i.e., no “normal” model).
Isolated studies using a particular cell type ex vivo — 
i.e., studies that extract blood/ respiratory/ immune 
cells and determine gene or protein expression in 
these cells.
Analysis of one component of a particular cell type 
(e.g., gene or protein expression).
Analysis of sputum or bronchoalveolar lavage (BAL) 
fluid from patient groups.
Any studies looking at novel formulations of 
drugs, modifying formulations of existing drugs, or 
attempting to improve the inhaled characteristics or 
delivery devices for drugs.
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Inclusion criteria Exclusion criteria
Review question: Define the suitability of a non-animal model for respiratory disease research
Area of applicability
The method deals with modelling of diseases of 
the respiratory system. In some cases, respiratory 
endpoints may be secondary, in which cases it should 
be clearly indicated how this contributes to further 
understanding of respiratory disease research.
The method clearly does not address issues related 
to respiratory disease.
Purpose and rationale for the method
The method addresses a scientific need, is based 
on sound scientific principles and is relevant for 
addressing the biological aspects and basis for 
respiratory disease.
The method has physiological relevance and is 
intended to be developed for wider use.
There are no clear indications as to the purpose, 
rational or biological plausibility of the method for 
respiratory disease research.
Method description 
The method itself is clearly described, in terms of the 
design of the test system, the biological endpoints 
under investigation, and the exposure regime where 
relevant. The value of each target endpoint is clearly 
explained.
The method is poorly or inadequately described, 
or does not indicate in adequate details important 
aspects such as exposure regime.
Research entity Involved
The method must come from a recognised research 
entity (Commercial, Educational, etc) with verifiable 
track record of research, and clearly identified so as 
to be contact for further information on the method, 
if required.
The source of the method is unclear and the research 
institute is unavailable for contact, or unwilling to 
answer questions about the status of the method.
Publication date
All studies published in the last 10 years (since 1 Jan 
2008). 
Studies published prior to 2008.
However, after identification of a first list of 
methods to be documented, specific searches shall 
be performed on the individual methods exceeding 
the given time-limit and extending the identified 
sources as appropriate and necessary for delivering 
an exhaustive and adequate description of the 
respective method.
Based on the large number of cancer abstracts 
retrieved, most of which were found to be not relevant 
in an initial sampling, it was agreed to restrict the 
search for cancer models to the past 5 years. 
Language
The search strategy will be tailored to searching 
in English language, however, no languages are 
excluded.
-
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Inclusion criteria Exclusion criteria
Review question: Define the suitability of a non-animal model for respiratory disease research
Publication type
Primary peer-reviewed studies (articles) and grey 
literature (e.g., conference proceedings, dissertations 
and theses, etc.). 
Secondary and tertiary studies (reviews, factbooks, 
etc.).
Where reviews are found, the primary sources will be 
referenced for inclusion.
Non-peer-reviewed sources (e.g., patents, 
communication letters, etc.)
Full text papers were retrieved for all accepted and ‘uncertain’ abstracts and individually reviewed 
for their relevance. Where a paper was found to describe a non-animal method and fit within the 
inclusion criteria, the details were extracted to a central MS Excel workbook. References that did 
not meet the inclusion criteria were included in a separate worksheet, with justification for their 
exclusion, referencing the agreed criteria.
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Field Field type Drop-down options Notes
Model number Number NA This number refers to a model of a 
respiratory disease which is described 
in a paper.
The same paper can describe more 
than a model.  
Disease Area Drop-down list For example:
Pulmonary disease - 
General
Asthma
COPD
Lung cancer
Pulmonary fibrosis
Cysic fibrosis
Upon abstract screening, papers are 
broadly categorised by disease area.
Disease Feature Drop-down list For example:
Elastin Viability
Exploratory/ no specific 
feature
Inflammation
Protein aggregation
Surfactant levels
Tissue/cell viability
Vasoconstriction
Specific endpoints of the disease with 
options for “Exploratory/ no specific 
feature”  and “na”. 
Category Drop-down list For example:
2D or 3D co-culture
Biochemical/cell-free assay
Chip or microfluidic system
Computational/in silico
Human/patient ex vivo 
tissue or body fluids
Human/patient primary or 
stem cells 
Human-derived cell lines
Organoid model 
Other
Papers were categorised during the 
screening phase of abstracts, using 
the some model types decided upfront.
Type Drop-down list For example:
Human pulmonary vascular 
smooth muscle cells
Human precision cut lung 
slices (PCLS)
Human samples from lung 
disease biobank (Germany)
Human nasal epithelial 
cells (hNECs)
RPMI2650 cell line
A549 cell line
HFL-1 cell line
More specifications, if applicable, on 
the model used. 
Table 2: Format of data extraction.
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Field Field type Drop-down options Notes
Application Drop-down list Project-specific, for 
example:
Comparison of barrier 
integrity
Diagnosis of disease
Disease mechanism (exp/
theor)
Disease therapy developm
Drug developm/ testing
Identification of biomarkers
Mimics lung 
microenvironment
Model development - 
experim
Model development - 
theoret
Model validation
Study of lung surfactant
Main scientific aim or application of 
the model. 
Biological endpoints Drop-down list For example:
Apoptosis
Chemotaxis
Cytokine Release
Gene expression
Imaging
Immunohistochemistry
Infection
Inflammatory mediators
Metabolism
mRNA expression
Phagocytosis
Protein
Repair
Tissue/cell Viability
List of potential biological endpoints, 
used in a model system to describe 
either the characteristics of a model or 
changes in the model system related 
to disease feature. 
Throughput Drop-down list High (automated)
Medium/low (lab scale)
Not relevant (e.g., in silico)
If applicable, the models is described 
in tems of throughput.
Potential Drop-down list For example:
Biomarker Discovery
Disease Progression
Drug Development
Drug Discovery
Mechanistic Studies
Pathogenesis
Toxic insult/response
Unknown
Potential for future development. This 
is subjective assessement.
Notes Free text NA Additional information.
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Field Field type Drop-down options Notes
Reference Free text NA Title of the paper which describes the 
model of respiratory disease.
DOI Free Text NA DOI and link of the paper which 
describes the model of respiratory 
disease.
Author Free Text NA Author(s) of the paper which describes 
the model of respiratory disease.
Year Free Text Automatically extracted 
from DOI
Year of Publication
Citation Index: 
Scopus and WoS
Drop-down NA Scopus and Web of Science citation 
indexes for the paper which describes 
the model of respiratory disease. 
It provides an indication of model 
maturity and use. It is automatically 
extraction from DOI reference.
Multidisciplinary citation databases and indexing services
Web of Science http://webofknowledge.com/WOS
Scopus http://www.scopus.com/ 
Google Scholar http://scholar.google.com/ 
Biomedical sciences citation databases
PubMed http://www.ncbi.nlm.nih.gov/pubmed 
Specific respiratory journals
European Respiratory Journal http://erj.ersjournals.com
American Journal of Respiratory Cell and Molecular 
Biology
https://www.atsjournals.org/journal/ajrcmb
American Journal of Critical Care Medicine https://www.atsjournals.org/loi/ajrccm
Chronic Respiratory Diseases http://journals.sagepub.com/home/crd
The Lancet Respiratory Medicine https://www.thelancet.com/journals/lanres/onlineFirst
Thorax http://thorax.bmj.com
Respiratory Research https://respiratory-research.biomedcentral.com/
articles
Journal of Cystic Fibrosis https://www.cysticfibrosisjournal.com
International Journal of COPD https://www.dovepress.com/international-journal-of-
chronic-obstructive-pulmonary-disease-journal
Table 3: Information sources that were considered in searches for scientific literature relating to the review 
questions.
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Specialised sources of information on respiratory disease research (publications, 
conference proceedings)
American Thoracic Society – ATS http://www.atsjournals.org
North American Cystic Fibrosis Foundation – NACFF https://www.cff.org
European Respiratory Society – ERS https://www.ersnet.org/#publications
Drug Discovery to the Lung – DDL https://aerosol-soc.com
Respiratory Drug Discovery – RDD https://www.rddonline.com
Commercial entities known to be developing respiratory disease models 
Epithelix http://www.epithelix.com
Mattek https://www.mattek.com
Emulate – lung-on-a-chip https://www.emulatebio.com/lung-chip
Mimetas – organ-on-a-chip https://mimetas.com
Specialised sources of information on non-animal methods 
UK National Centre for the Replacement, Refinement & 
Reduction of Animals in Research (NC3Rs)
https://www.nc3rs.org.uk
Norwegian Inventory of Alternatives (NORINA) https://norecopa.no/NORINA
Fund for the Replacement of Animals in Medical 
Experiments (FRAME)
http://www.frame.org.uk
Center for Alternatives to Animal Testing (CAAT) http://caat.jhsph.edu
European Union Reference Laboratory for alternatives 
to animal testing (EURL ECVAM)
https://ec.europa.eu/jrc/en/eurl/ecvam 
https://ecvam-dbalm.jrc.ec.europa.eu
OECD Test guidelines and guidance on non-animal, 
mechanistic methods
http : / /www.oecd .org /chemicalsafety / test ing/
oecdguidelinesforthetestingofchemicals.htm
http://www.oecd.org/chemicalsafety/testing/adverse-
outcome-pathways-molecular-screening-and-
toxicogenomics.htm
Hits Specific search term 
15,764 TS=((("in vitro" OR "in silico" OR "ex vivo" OR "3r" OR "non animal" OR "animal 
alternative*" OR organoid*) AND ("respirat*" OR "lung" OR airway* OR alveol*)) AND 
("lung cancer"))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=2006-2018
17,247 TS=(((“in vitro” OR “in silico” OR “ex vivo” OR “3r” OR “non animal” OR “animal 
alternative*” OR organoid*) AND (“respirat*” OR “lung” OR airway* OR alveol*)) AND 
(“lung cancer” OR “lung carcino*”))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=2006-2018
Table 5: Respiratory disease non-animal models — pilot search outputs.
Table 4: Organisations relevant to respiratory disease modelling and non-animal methods.
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Hits Specific search term 
24,980 TS=(((“in vitro” OR “in silico” OR “ex vivo” OR “3r” OR “non animal” OR “animal 
alternative*” OR organoid*) AND (“respirat*” OR “lung” OR airway* OR alveol*)) AND 
(cancer* OR carcino* OR neoplas*))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=2006-2018
4,069 TS=(((“in vitro” OR “in silico” OR “ex vivo” OR “3r” OR “non animal” OR “animal 
alternative*” OR organoid*) AND (“respirat*” OR “lung” OR airway* OR alveol*)) AND 
(“fibrosis” OR “cf”))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=2006-2018
1,367 TS=(((“in vitro” OR “in silico” OR “ex vivo” OR “3r” OR “non animal” OR “animal 
alternative*” OR organoid*) AND (“respirat*” OR “lung” OR airway* OR alveol*)) AND 
(“copd” OR “chronic obstructive pulmonary disease”))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=2006-2018
3,786 TS=(((“in vitro” OR “in silico” OR “ex vivo” OR “3r” OR “non animal” OR “animal 
alternative*” OR organoid*) AND (“respirat*” OR “lung” OR airway* OR alveol*)) AND 
“asthma”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=2006-2018
Specialised chemistry-oriented databases
Chemical Abstracts (SciFinder) http://www.cas.org/products/scifinder 
Multidisciplinary citation databases and indexing services
Web of Science http://webofknowledge.com/WOS
Scopus http://www.scopus.com/ 
Biomedical sciences citation databases
PubMed http://www.ncbi.nlm.nih.gov/pubmed 
Table 6: Information sources used in literature searches.
Annex 69
Table 7: Number of models per disease area mapped against disease feature.
Disease area
Disease feature
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
Exploratory/no specific feature 1 1 5 12 1 26 46
Inflammation 1 12 4 1 1 2 6 1 28
Tissue/cell viability 1 1 1 2 3 11 2 3 3 27
Tumour microenvironment 23 23
Airway remodelling 11 2 13
Gene expression 2 2 7 1 1 13
Toxicity 1 11 1 13
Barrier function/integrity 1 2 3 1 4 1 12
Infection 1 3 8 12
Protein expression 1 1 2 5 1 2 12
Idiopathic pulmonary fibrosis 
(IPF)
10 10
Mucous production 3 3 2 2 10
Metastasis 9 9
Angiogenesis 2 3 1 2 8
Drug resistance (chemotherapy) 7 7
Epithelial/fibroplastic cross-talk 1 1 1 3 6
Healing/repair 2 1 1 2 6
Epithelial mesenchymal 
transition (EMT)
4 1 5
Structural changes 1 1 1 1 1 5
Oxidative stress 1 3 4
Bronchoconstriction/
bronchodilation
2 1 3
Elastin viability 1 1 1 3
Primary ciliary dyskinesia (PCD) 2 1 3
Small airway smooth muscle 2 1 3
Bronchial dysplasia 1 1 2
CTFR Activity 2 2
EGF/EGFR expression 2 2
Mucosal clearance 2 2
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Disease area
Disease feature
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
Protein aggregation 1 1 2
Airflow patterns 1 1
Chloride channel function 1 1
Emphysema 1 1
Goblet cell metaplasia 1 1
Hypoxia 1 1
Senescence 1 1
Sensitisation 1 1
Surfactant levels 1 1
Vasocontriction 1 1
Total per disease area 3 42 3 29 30 97 21 70 4 1 300
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Table 8: Model categories mapped against disease area.
Disease area
Model category/type
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
2D or 3D culture 2 14 2 4 12 26 7 30 2 99
2D or 3D co-culture 2 4 2 27 2 12 1 1 51
Human/patient primary or stem 
cells
13 8 4 4 7 1 37
Human/patient ex vivo tissue or 
body fluids
1 7 10 2 5 4 4 33
Chip or microfluidic system 1 1 12 3 4 21
Computational/in silico 4 1 2 9 1 3 20
Spheroid 2 6 1 1 10
3D spheroid co-culture 6 1 7
Organoid model 1 5 6
Other 1 5 6
Bioreactor 1 3 4
Biochemical/cell-free assay 1 1 1 3
Human-derived cell lines 1 2 3
Total per disease area 3 43 3 28 26 98 22 72 4 1 300
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Disease area
Cell type/cell line
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
A549 cell line 3 41 5 6 55
HBEC 5 4 2 5 16
Other 14 14
Primary human bronchial 
fibroblasts
4 2 4 2 12
Primary human NHBE cells 1 1 3 6 1 12
Human nasal epithelial cells 
(hNECs)
3 3 5 11
16HBE14o- human bronchial 
epithelial cell line
1 1 1 1 7 11
Primary human tracheobronchial 
epithelial cells 
4 2 3 1 10
Human lung tumour tissue 8 8
In silico/mathemathical model 2 1 1 1 3 8
Calu-3 1 5 1 7
Human precision cut lung slices 
(PCLS)
1 3 1 2 7
MCR5 fibroblasts 1 1 5 7
Bronchial epithelial biopsy tissue 4 1 1 6
H1299 human lung carcinoma 6 6
Human airway smooth muscle 
cells (HASMCs)
4 1 1 6
Human bronchial smooth 
muscle cells (HBSMC)
4 2 6
Human lung microvascular 
endothelial cells HMVEC
2 2 1 1 6
Human pulmonary vascular 
smooth muscle cells
3 1 1 1 6
See notes 1 1 2 2 6
Human fetal lung fibroblasts 
IMR-90
5 5
HUVEC ATCC 5 5
Mesenchymal stem cells (MSCs) 4 1 5
Primary human ASMCs 2 1 2 5
Table 9: Cell types mapped against disease area.
Annex 73
Disease area
Cell type/cell line
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
THP-1 cell line 4 1 5
3T3 mouse fetal fibroblasts 4 4
Airway epithelial ALI culture 1 1 1 1 4
Alveolar epithelial type II (ATII) 
cells 
1 1 2 4
H460 human lung carcinoma 4 4
Human airway epithelial cells 
(CFBE41o)
4 4
Human airway epithelial cells 
(hAEC)
1 1 1 1 4
Human airway epithelial cells of 
nasal origin (hAECN)
2 1 1 4
MRC5 fibroblasts 3 1 4
16HBE 3 3
Cystic fibrosis human bronchial 
epithelial (CFBE) cells
3 3
H358 bronchioalveolar 
carcinoma
3 3
HCC827 3 3
Human dendritic cells (DC) 3 3
Human MDDC monocyte-derived 
dendritic cells
3 3
Human PBMC 2 1 3
Human Pericytes 2 1 3
Human small airway epithelial 
Cells (SAEC)
1 2 3
Lung tissue (unspecified) 2 1 3
Lung-cancer associated 
fibroblasts
3 3
MRC-5 1 1 1 3
NCI-H1975 3 3
95-D human lung carcinoma 2 2
BEAS-2B 1 1 2
Cytokine-induced killer cells 2 2
H1650 2 2
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Disease area
Cell type/cell line
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
H292 human lung tumour 2 2
HEK293T cells 2 2
Human lung parenchyma 2 2
Human MDM monocyte-derived 
macrophages
1 1 2
Human nasal turbinate slices 1 1 2
Human NSCLC 2 2
Human primary dermal 
fibroblasts
2 2
Human primary neutrophils 1 1 2
Human pulmonary artery 
endothelial cells (HPAEC)
1 1 2
Human pulmonary artery tissue 1 1 2
Human pulmonary epithelial cell 
lines NCI-H441
1 1 2
HUVEC isolated from human 
umbilical cords 
2 2
Induced pluripotent stem cell-
derived mesenchymal stem cells 
(iPSC-MSCs) 
1 1 2
Lewis lung cancer LLC 2 2
Macrophages 2 2
NCI-H460 2 2
Normal human lung fibroblasts 2 2
Precision cut lung slices 2 2
Primary human airway epithelial 
(PHAE) cells
1 1 2
Small airway epithelial cells 
(SAEC)
2 2
SPCA-1 human lung 
adenocarcinoma
2 2
Wi-38 human fibroblasts 1 1 2
1205Lu metastatic melanoma 1 1
1HAEo2 cells 1 1
3T3J2 swiss mouse fibroblast 
cell line
1 1
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Disease area
Cell type/cell line
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
3T3-L1 pre-adipose cells 1 1
Alveolar macrophages 1 1
Anip973 1 1
BAL Eosinophils 1 1
BEAS2B 1 1
BJ fibroblasts 1 1
Calu-6 1 1
Cancer-associated fibroblasts 
(LuCAFs)
1 1
CCL-153 1 1
CCL-210 fibroblasts 1 1
CF cell line (CuFi-1) 1 1
CFBE41o- 1 1
Colo66 1 1
Cystic fibrosis bronchial 
epithelial cell line (CF8Flp)
1 1
Decellularised human lungs 1 1
Endobronchial biopsy specimens 
(EBBs)
1 1
EpiAirway (primary BEC) 1 1
Erythroleukaemia cells 1 1
H292 human muco-epidermoid 
bronchiolar carcinoma cell line 
(ATCC)
1 1
H446 1 1
H520 1 1
H69 1 1
HBEC-4 1 1
HepRG (liver cells) 1 1
HFL-1 cell line 1 1
Human adipose-derived stem 
cells (hASCs)
1 1
Human airway epithelium (NuLi-1) 1 1
Human bronchial smooth 
muscular thin films (bMTF)
1 1
Human CL-1548 cells 1 1
Human ECFC-EC endothelial 
cells
1 1
Human fetal airway smooth 
muscle (ASM) cells
1 1
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Disease area
Cell type/cell line
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
Human lung adenocarcinoma 
(HCC)
1 1
Human lung fibroblasts 1 1
Human microvascular 
endothelial cells
1 1
Human neonatal dermal 
fibroblasts
1 1
Human parenchymal lung tissue 1 1
Human pluripotent stem cells 
(hPSCs)
1 1
Human primary pulmonary 
artery smooth muscle cells 
(PASMC) 
1 1
Human Reconstituted Nasal 
Epithelium (hRNE)
1 1
Human small cell lung cancer 
WA-hT
1 1
Immortalised human fetal 
hepatocytes
1 1
Induced pluripotent stem cells 
(iPSCs)
1 1
Jurkat E6.1 T cells 1 1
Mai9 human malignant pleural 
effusion-derived
1 1
MeT-5A human pleural 
mesothelial cell line (PMC) 
1 1
Mouse 344SQ cells 1 1
Mouse lung adenocarcinoma 
Lacun. 3
1 1
Mouse lung epithelial cells 1 1
Mouse stromal fibroblasts WA-
mFib cells
1 1
Murine 344SQ 1 1
Murine 393P 1 1
Myeloid-derived suppressor cells 1 1
Nasal ciliary cell sheets (human-
derived)
1 1
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Disease area
Cell type/cell line
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
Nasopharyngeal cancer cell line 1 1
NCI-H157 1 1
NCI-H1993 1 1
NCI-H292 cells 1 1
NCI-H522 1 1
NCI-H596 1 1
NHBE cell line 1 1
NIH 3T3 murine fibroblast cells 1 1
OncoCil Air™ cultures 1 1
Patient serum 1 1
Perivascular cells 1 1
Primary bronchial epithelial cells 
(PBEC)
1 1
Primary HAEC at ALI 1 1
Primary human BEC 1 1
Primary mouse lung fibroblasts 1 1
Rat heart-lung block 1 1
RPMI2650 cell line - nasal 
mucosa
1 1
SHP77 1 1
Synthetic sputum 1 1
VXN2 - primary lung tumour cell 
line
1 1
WM852 metastatic melanoma 1 1
Xenograft tumour tissue 1 1
Total per disease area 4 51 5 32 32 198 30 89 4 3 448
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Disease area
Application of the model
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
Model development/experim 1 4 1 2 12 30 2 38 90
Disease mechanism (exp/theor) 2 28 12 4 13 11 12 1 83
Drug development/testing 1 3 21 1 6 32
Disease therapy development 3 5 2 11 4 3 28
Mimics tumour 
microenvironment
14 14
Model development – theoret 2 1 1 4 1 9
Mimics lung microenvironment 1 1 2 3 7
Toxicity 2 1 4 7
Model of human airway mucosa 1 1 1 2 5
Comparison of barrier integrity 1 2 3
Diagnosis of disease 2 1 3
Identification of biomakers 1 1 1 3
Inhalation toxicity 2 2
Disease treatment 1 1
Lung injury 1 1
Model validation 1 1
Study of lung surfactant 1 1
Total per disease area 3 41 3 27 25 96 21 69 4 1 290
Table 10: Application of the models mapped against disease area.
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Disease area
Biological endpoints
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
Protein expression 13 1 13 3 4 13 48
Gene expression 1 8 10 4 10 3 10 46
Cytokine release 1 11 1 5 1 4 5 14 3 45
Other 6 5 3 6 6 17 43
Tissue/cell viability 3 2 1 1 17 3 12 2 41
mRNA expression 2 5 5 3 1 5 13 34
Immunohistochemistry/
immunofluorescence
6 8 6 5 6 31
Imaging 2 5 4 2 1 14 28
Trans epithelial electrical 
resistance (TEER)
3 2 1 2 4 11 1 24
Inflammatory mediators 6 1 3 1 1 2 1 15
Metabolism 1 1 13 15
Migration and invasion 15 15
Cillia beating frequency 5 5 10
Cellular crosstalk 8 8
CTFR Activity 6 2 8
Morphology 1 7 8
Vascularisation 1 4 1 1 7
Apoptosis 1 2 3 6
Cell/tissue morphology 2 1 2 1 6
Cell proliferation 2 1 1 1 5
Mucous production 1 1 2 1 5
Bioelectric Properties 3 1 4
Cell/tissue contraction 1 1 2 4
Chemotaxis 2 1 1 4
Airway remodelling 1 1 1 3
Cell migration 1 2 3
Epithelial mesenchymal 
transition (EMT)
1 2 3
Mucociliary clearance 1 2 3
Table 11: Biological endpoints mapped against disease area.
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Disease area
Biological endpoints
Allergic rhinitis
Asthm
a
Cigarettes
CO
PD
Cystic fibrosis
Lung cancer
Pulom
onary fibrosis
Respiratory disease 
- general
Toxicity
Tuercolosis
Total
Airway surface liquid (ASL) 
volume
1 1 2
(Cyto)toxicity 1 1 2
Infection 1 1 2
Reactive oxygen species (ROS) 1 1 2
Repair 1 1 2
Airway constriction 1 1
Cell motility 1 1
DNA damage 1 1
Elastin levels 1 1
Intracellular Ca2+ changes 1 1
Macrophage activity 1 1
Mitochondrial membrane 
potential (δΨm)
1 1
Mucosal tissue 1 1
Myofibroblast differentiation 1 1
Phagocytosis 1 1
Proliferation 1 1
Protein 1 1
Wnt signaling pathway 1 1
Total per disease area 11 81 11 68 44 93 42 136 8 1 495
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